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2Abstract
Nitrogen-containing spiro-cyclic compounds mainly exist in naturally occurring compounds and 
pharmaceutical products. Spiro-cyclic frameworks are characterized by a unique special 
arrangement of their rings. The main challenge for the preparation of the spirocyclic motif is 
regio-controlled and stereo-controlled generation of a quaternary carbon center. Known methods for 
spiro-cyclic compounds include alkylation and cyclisation, condensation reactions, rearrangement 
reactions, metal-catalysed reactions, and ring closing metathesis are reviewed. Brønsted 
acid-catalysed hydroamination in the synthesis of pyrrolidines and spiro-pyrrolidines has been 
investigated in the Knight group for a long time. This methodology is of great convenience and can 
be efficient for targeted cyclic and spiro-cyclic compounds synthesis. A tris-piperidine structure, a 
potential lead compound for an ant-cancer drug, originates from a computer study carried out at 
Cancer Research UK. This small molecule was found which could bind to known sites present in 
various cancer cells.
This thesis describes the application of triflic acid-catalysed cyclisation in the synthesis of the 
targeted spiro-piperidines and tris-piperidines. In section one, an introduction of anticancer drugs 
and anticancer drugs discovery is given, together with the background of the current project. Section 
two summarizes known methods for spiro-cyclic compounds synthesis, and applications of triflic 
acid-catalysed cyclisation in the Knight group are reviewed in section three. Section four describes 
different synthetic routes towards the construction of amino-alkenes and cyclisation into spiro-cyclic 
compound via acid-catalysed hydroamination methodology. Attempts to synthesize 
1,3-disubstituted-dithianes for the preparation of spiro-piperidine and tris-piperidine are also 
discussed. Chapter five contains the experimental data.
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5Abbreviations
Abbreviations used in this thesis are listed below:
Ac acetyl
APCI atmosphere pressure chemical ionisation 
br. broad
Bn benzy
Bz benzoyl
BuLi butyl lithium
cat. catalytic
cy cyclohexane
d day(s)
d doublet
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCM dichloromethane
dd double doublet
DEAD diethyl azodicarboxylate
DIAD diisopropyl azodicarboxylate
DMAP 4-dimethylaminopyridine
DMF dimethyl formamide
DNA           deoxyribonucleic acid 
DPC diphenyl chlorophosphine
DPPA diphenylphosphoryl azide
dt              double triplet
DTBMP 2,6-di-tert-butyl-4-methylpyridine
eq. equivalent(s)
g gram
h hour(s)
6HTS            high throughput screening
HRMS high resolution mass spectroscopy
Hz hertz
IR infra-red
J coupling constant
m multiplet
M molar
Me methyl
min. minute(s)
ml millilitre(s)
mmol           millimole(s)
m.p.            melting point
MS             mass spectrometry
NMR           nuclear magnetic resonance
PABA          p-aminobenzoic acid
TBDMS tert-butyldimethylsilyl
ppm            parts per million
q              quartet
RCM           ring closing metathesis
RNA ribonucleic acid
RRM           ring rearrangement metathesis
r.t.             room temperature
s              sigma
s singlet
t triplet
THF           tetrahydrofuran
7Section 1: Introduction
81.1 Cancer
Cancer is a large group of diseases characterized by abnormal cell growth. It has become the second 
leading cause of death worldwide. In 2012, there were 14.1 million new cancer cases and 8.2 million 
deaths resulted from cancers (Figure 1). It is estimated that the number of new cancer cases will rise 
to 22 million within the next decades.1
Figure 1. Worldwide cancer statistics in 2012 (Cancer research UK).
Cancer is caused by genetic alterations. In normal cells, the division and replication of cells is 
controlled by the activity of genes. When some genes are faulty, they can malfunction and cause 
excessive cell growth. Researchers found that genetic alterations were not only caused by mutation 
in oncogenes and tumor-suppressor genes, but also by epigenetic alterations.2
Cancer treatments have changed with the understanding of the underlying biological processes of 
neoplastic tumors. The most serious obstacle to cancer treatment is the complexity and plasticity of 
cancer cells. Depending on the type, location and grade of cancer, treatment of cancers will be 
different. Common primary treatments include surgery, chemotherapy, radiotherapy, hormonal 
therapy and targeted therapy. Surgery may play a role in prolongation of survival. However, the 
effectiveness of the treatment is often limited by metastasis. In combination with surgery, 
chemotherapy as a part of standardized treatment has proven useful in numerous cancers. The 
toxicity of the agents used in chemotherapy is still a problem, which needs to be considered. 
9Compared with many standard chemotherapy agents, targeted agents are more specific and less toxic. 
Survival rates of various types of cancer have dramatically improved as a result of the discovery and 
development of novel anti-cancer agents. Until now, there are more than ten targets, which have 
been developed in current cancer therapy (Figure 2).
Figure 2. Various mechanism of action of anticancer agents.3
1.2 Anti-cancer drugs
Although various mechanisms of action of chemotherapeutic drugs have been described, the main 
aim of anticancer drugs is to interfere with tumor growth and progression. Agents that interact with 
deoxyribonucleic acid (DNA) processing are the largest and most diverse group of anticancer agents. 
Generally, there are seven classes of anticancer agents: alkylating agents, antimetabolites, anticancer 
antibiotics, natural products, miscellaneous agents, hormonal agents, and target-based agents.
Alkylating agents play an important role in cancer treatment. These are cytotoxic drugs that attach 
an alkyl group to biomacromolecules such as DNA, ribonucleic acid (RNA) and enzymes. The 
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alkylated part is essential for anticancer activity and changes to the carrier part can improve 
pharmacokinetics properties in the body (Figure 3).
Figure 3. General structure of alkylating agents
The anticancer drug mechlorethamine is the prototype of alkylating agents. The successfully 
clinically used mechlorethamine promoted the later development of more alkylating agents 
including the nitrogen mustards, ethyleneamine derivatives, alkyl sulfonates, nitrosoureas and 
platinum coordination complexes. The usual reaction mechanism associated with such alkylating 
agents is first displacement of chloride to form an electrophilic aziridinium ion, which is then 
attacked by nucleophilic DNA bases (Figure 4). One of the other cross-link strands of DNA will 
repeat the reaction sequence, leading to DNA damage. This action works for all cells, but cancer 
cells are more sensitive because of their rapid dividing rate. Even though the newly developed 
anticancer drugs have been used to achieve better clinical outcomes, sometimes alkylating agents 
represent a unique treatment option for refractory tumors.4
Figure 4. Reaction mechanism of alkylating agents
Antimetabolites have a similar chemical structure to naturally occurring molecules in DNA and 
RNA synthesis. Purine and pyrimidine analogues and anti-folate agents are widely used clinically to 
stop cell development and division (Figure 5). These are phase specific agents that only act on phase 
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S. These were thought to act on fast growing cancer cells, but cells in hair, bone marrow, and the 
gastrointestinal (GI) tract also respond and lead to unavoidable side effects. Moreover, the less
active cells in older solid tumors make these types of agents less effective. 
Figure 5. Clinically used antimetabolites.
An antimetabolite may be an antibiotic. Sulfonamide antibiotics are a kind of p-aminobenzoic acid 
(PABA) inhibitor, which affect the production of folic acid by competitively inhibiting the 
enzymatic synthesis of PABA.
Many clinically used anticancer antibiotics have been derived from Streptomyces species. These 
antibiotics act by blocking the synthesis of DNA and RNA, or by affecting topoisomerase II. 
Compared with traditional chemotherapeutic agents, such antibiotics specifically bind to cancer cells 
to inhibit cell growth, while having limited effect on healthy cells and such antibiotics can also be 
used to treat or prevent infections during cancer treatment. Anticancer antibiotics have become an 
accepted treatment for some types of cancer. Doxorubicin and daunorubicin are the most important 
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and useful antibiotics that can be used to treat more than one type of cancer. Doxorubicin is mainly 
used to treat acute leukemia and the combination of daunorubicin and methotrexate may treat 
localized or disseminated gestational choriocarcinoma. Antiobiotics such as actinomycin D, 
epirubicin, bleomycins and mitomycin C have also been widely used in cancer treatment.
Natural products and their derivatives are a most important source of anticancer agents, either in 
their naturally occurring forms or as synthetically modified derivatives (Figure 6).5 Much effort has 
been put into the isolation of lead compounds with potential bioactivity, chemical modification of 
effective constituents from natural products and the development of efficient total synthesis or 
semi-synthesis routes.
Figure 6. Anticancer drugs from natural source.
Doxorubicin Daunorubicin
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Vinblastine is an important basic medicine that is on the list of essential medicines. It is a phase 
specific agent that arrests phase M in a cell cycle. Vinblastine works by inhibiting mitosis and has 
been used to treat numerous cancers including Hodgkin’s lymphoma, bladder and brain cancer and 
non-small cell lung cancer. The combination of vinblastine, methotrexate and bleomycin has been 
reported effective in the treatment of early stage Hodgkin’s lymphoma.6 Paclitacel (Taxol®) is 
another well-known anticancer agent isolated from yew, which is currently used to treat lung and 
breast cancer. Two camptothecin analogues, topotecan and irinotecan, have been approved in cancer 
chemotherapy.7 Resveratrol, a widely occurring natural phenol, was found to be a potential cancer 
chemo-preventive agent that can affect progression though S phase and G2 phase of a cell cycle.8,9 
Hormones are substances made naturally in the body that stimulate and regulate body functions. 
Hormone-sensitive or hormone-dependent cancers, such as breast and prostate cancer, can be 
managed by blocking the effects of these or lowering their levels. Treatment of breast cancer in 
premenopausal and postmenopausal women is different due to the way that production of oestrogen 
is different. Aromatase inhibitors such as anastrozole, exemestane and letrozole are used to treat 
early breast cancer in postmenopausal women by blocking the production of oestrogen in body fat. 
For premenopausal women with breast cancer, luteinising hormone (LH) blockers act on a hormone 
produced in the pituitary gland to stop the production and release of oestrogen from ovaries. Ovary 
removal by surgery is another treatment option for premenopausal women. Hormone agents cannot 
only treat hormone sensitive or hormone dependent cancers, but also prevent such cancers from 
occurring and recurrence. A large international clinical trial showed that taking tamoxifen for 10 
years after primary treatment of breast cancer leads to a noticeable reduction in cancer recurrence 
and death.10
In the past five years, 40% of the best-selling anticancer drugs are targeted agents. Targeted therapy 
seems more effective than traditional chemotherapy and provides more individualized and effective 
treatment for cancer patients. It interferes with specifically targeted molecules needed for tumor 
growth rather than with a rapidly dividing cell. G-protein-coupled receptors, protein kinases and 
monoclonal antibodies have become a very important group of anticancer drug targets. 11
Monoclonal antibodies are man-made versions of immune system proteins that can be designed to 
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attack specific cancer cells. Immunotherapy is another biologically targeted therapy that is designed 
to stimulate the body’s immune system to attack cancer cells.
1.3 Anti-cancer drug discovery
Drug discovery is a time-consuming and expensive business. Generally, there are seven stages 
(Figure 7). Target identification is the first and crucial step in the drug discovery process. It can take 
many years to build up supporting evidence before selecting a target in a drug discovery program. A 
good target should be efficacious, safe and also meet clinical and commercial needs. Genomics and 
proteomics technologies have been used to identify a biological target that presents a common 
feature of a particular disease. Newly developed phenotypic screening is successfully used to isolate 
human monoclonal antibodies (mAbs). Once a target is identified, this then needs to be validated. 
Target validation is a multifunctional process: it is often considered that drugs failing to reach the 
clinic are the result of sloppy early target validation.12
Figure 7. Drug discovery process
A hit is the output of a compound screening that can be defined as a compound with a desired 
activity. Based on the knowledge of the target, hits are selected from numerous molecular sources 
and chemical libraries. Nowadays, high throughput screening (HTS) methods are widely used to 
generate a series of compounds with the desired activity. A chemistry program is started after 
screening to improve both the potency and selectivity of the initial hit.
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Hit series are generated and selected to further develop to make “druglike” molecules. A potential 
winner is finally generated from such a hit series. This is one of the most challenging processes in 
drug discovery due to the difficulties of making and designing a molecule that is “drug-like”.
Lipinski’s rule of five is a useful rule to predict drug-likeness. It is used to indicate if a certain 
compound with pharmacological or biological activity can be an orally active drug in humans. Good 
absorption or permeation of a compound is more likely when a particular molecule has less than five 
hydrogen bond donors, less than ten hydrogen bond acceptors, a molecular weight under 500 and a 
partition coefficient (LogP) value under five. Increasing molecular weight may lead to safety and 
tolerability issues. If there are two parameters are out of the range, poor solubility or permeability is 
considered likely.13 The majority of clinically marketed drugs normally have molecular weights of 
less than 350 and LogP values of less than 3.14 Ultrafast shape recognition (USR) software has been 
developed recently to help identify drug-like molecules that have beneficial biological properties. 
This newly developed technique is 1,400 times faster than other technique currently used in virtual 
screening for drug discovery.
The goal of lead optimization is to find a drug candidate that has the desired biological properties as 
well as good absorption and is effective and safe. Data related to efficacy, stability, bioavailability 
and toxicity also have to been tested. Combinations of rapid in vivo and in vitro drug metabolism 
and pharmacokinetics (DMPK) screening tools have been used in the development of compounds 
with acceptable DMPK parameters.15 The most-performing compound will then be chosen to enter 
pre-clinical studies.
Combinatorial chemistry is a new techniques developed to create a large population of chemical 
libraries in a short time. It speeds up drug discovery. Numerous structurally different molecules will 
be screened for biological activity by high throughout screening or used for pharmacological 
assay.16 Combinatorial chemistry was first used in syntheses of peptide libraries that might be active 
in regulating human physiological responses. Some polypeptide libraries were found to be useful in 
the treatment of cancer.17 There is a natural product-like library that has been built that contains 
2.81 million polycyclic compounds. These compounds will be used to explore biological pathways 
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by combining with chemical genetic assays and biological functions by reverse chemical genetic 
assays.18
An important aspect of natural products is to provide biodiversity. Plant-derived compounds have 
been an important source of clinically useful agents. One in four drugs used in the past 20 years is
directly derived from plants, while another 25% are chemically altered natural products. 19
Compounds isolated from plants, marine flora and microorganisms can be lead compounds for 
further research.20 More than 3000 plant species have been found that can be used in the treatment 
of cancer.21 The taxoids such as Paclitaxel (Taxol®) and Docetaxel (Taxotere®) represented a novel 
class of antineoplastic drugs. Paclitaxel was isolated from the bark of the Pacific Yew, Taxus 
brevifolia. It is a cytoskeletal drug that interacts with tubulin. Unlike other tubulin-targeted drugs, 
paclitaxel stabilises microtubule polymer and prevent mitosis instead of inhibiting microtubule 
assembly.
The unique structure of taxol has attracted organic chemists for decades. Seven independent total 
syntheses have been reported by Holton22, Nicolaou23, Danishefsky24, Wender25, Kuwajima26, 
Mukaiyama27 and Takahashi28 respectively. Wender described the shortest synthesis of taxol (37 
steps) in a linear manner with ring construction in the order of A, B, C, and D (Figure 8).29 The 
overall yield was only 0.4% and clearly has no commercial value.
Figure 8. Paclitaxel
Commercial semi-synthesis of paclitaxel starts from the related yew metabolite, 10-deacetylbaccatin 
III. Taxol is produced through selectively protection of the hydroxyl on carbon 7, esterification of 
hydroxyl on carbon 10, side-chain addition and deprotection (Scheme 1).
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Scheme 1. Semi-synthesis of taxol
The low water solubility (0.03 mg/ml) of paclitaxel limits its clinical use. The synthesis of natural 
compounds analogues could improve efficacy and reduce toxicity.30 Docetaxel (Figure 9), an 
analogue of paclitaxel, was synthesized from extracts of the needles of the European yew tree. Two 
positions differ from paclitaxel, a hydroxyl group on C-10 and an ester group on the 
phenylpropionate side chain. The changing of the carbon 10 functional group leads to better water 
solubility of docetaxel. In clinical practice, docetaxel was proven to have greater benefits than 
paclitaxel in terms of survival and time to disease progression in the treatment of metastatic breast 
cancer.31
Figure 9. Structure of docetaxel
At an early stage of anticancer drug discovery, the conventional method is to scan thousands of 
compounds from natural sources that could represent the target. This approach is time-consuming 
and of low productivity. With the gradual understanding of the fundamental biochemistry of cancer 
cells, rational drug design approaches have been developed. It is relatively easy to find the structure 
of the target and then design a lead compound to fit this. Based on drug-receptor or drug-enzyme 
interactions, rational drug design begins with a hypothesis that a specific designed target may have 
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therapeutic value. The specific target should be a drug-like compound and the information of the 
therapeutic value may come from the disease linkage studies. Incorporation of gene expression 
technology and bioinformatics tools would be indispensable in the structure based drug design.
Moreover, affinity for the target can be predicted before it is synthesized.
One successful example of rational drug design is the development of Imatinib (Glivec®), which is a 
tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia (CML). A series of 
2-phenylaminopyrimidines was identified as lead compounds by testing compound libraries in vitro 
(Figure 10). Structure-activity relationship (SAR) studies showed that the methyl substitution of the 
aniline-phenyl ring at C-6 position led to potent bioactivity, and the introduction of an N-methyl 
group to the piperazine improved the absorption, distribution, metabolism and excretion properties.32
Figure 10. Discovery of imatinib.
Biological targets of currently used drugs may not be fully identified when the drug was originally 
developed. Drug repositioning is an attractive form of drug discovery. There are approximately 30% 
of newly approved drugs and vaccines resulted from drug repositioning. In order to get the 
maximum both clinical and commercial benefits from current available drugs, a comprehensive 
understanding of biological and pharmaceutical knowledge and certain mechanism-of-action of 
drugs is required.
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Artemisinin (Figure 11), also known as Qinghaosu, is an example of drug repositioning. It was 
originally used as a standard treatment worldwide against Plasmodium falciparum malaria. The 
outstanding characteristics of artemisinin and its derivatives include rapid action, less significant 
side effects and less drug resistance. In addition to its antimalarial properties, artemisinin and its 
analogs have been found to be potentially inexpensive and effective cancer agents.33 Hundreds of 
papers have reported this anticancer activity since 1992. Due to the different amount of intracellular 
free ions in cancer cells and normal cells, artemisinin and its analogs can selectively cause apoptosis 
in many cancer cell lines. 34 Moreover, artemisinin compounds have been found to have 
anti-angiogenic, anti-inflammatory, anti-metastasis and growth inhibition effects.35 Other successful 
drug repositioning for anticancer applications include Itraconazole, Nelfinavir, Digoxin, Nitroxoline, 
Riluzole, Mycophenolic acid and Disulfiram.
Figure 11. Artemisinin
Monoclonal antibodies play an important role in modern cancer treatment. About 40% of the 
best-selling anti-cancer drugs are monoclonal antibodies, which were discovered by basic research 
into the mechanism of generation of antibody diversity.36 The greatest advantage of monoclonal 
antibodies is these molecules can be used equally in research, diagnose and the treatment of 
cancer.37 The first approved monoclonal antibody treatment for cancer was Rituxan. It has been 
approved to treat a number of cancers including non-Hodgkin’s lymphoma (NHL), chronic 
lymphocytic leukemia (CLL) and rheumatoid arthritis (RA). The life saving drug Bevacizumab 
(Avastin) is the first clinically used angiogenesis inhibitor that slows the growth of new blood 
vessels by inhibiting vascular endothelial growth factor A (VEGF-A).
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1.4 Background of current project
This project originates from a computer study carried out at Cancer Research UK, which was part of 
an extensive search aimed at identifying novel and previously untested structures that could become 
lead compounds in future efforts to obtain new treatments for cancers of any type using such small 
molecule therapy. The overall aim was to try to occupy previously unexplored areas of molecular 
space. This was achieved by taking known binding sites present in various cancer cells consisting of 
proteins with established structures and using the computer to generate molecules that bind 
reasonably strongly to such structures. In this way, the rather unusual tris-piperidine structure 1 was 
generated. Having two spiro-centres and three stereogenic carbons and hence eight possible 
stereoisomers, this satisfies exactly the aim of this computational study in thus proposing a 
completely novel structure.
As yet, this structure or any derivatives have not been published; the compound came to the 
attention of Professor David Knight when he attended a lecture given by Professor Keith Jones, the 
Director of compound discovery at Cancer Research UK. Clearly, compound 1 presents a significant 
synthetic challenge; in addition, once the basic skeleton has been formed, the stereo-chemical 
aspects will have to be considered as well, as illustrated in structures 2-5. An additional 
complication is that 2-substituted-piperidines tend to exist in conformations wherein such a group is 
positioned axially rather than the expected equatorial position, when the adjacent nitrogen is 
substituted as illustrated by the perhaps surprising equilibrium between structures 6 and 7 (scheme 
2).
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Scheme 2. Proposal equilibrium of substituted-piperidines
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Section 2: Known methods for spiro-cyclic compound synthesis
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Spiro compounds are molecules containing two rings connected with one shared atom (the spiro
atom). Spirocyclic frameworks are characterized by a unique special arrangement of their rings. By 
adding functional groups in one or two rings, a broad diversity of structures can be achieved.
Azaspirocycles are nitrogen-containing spirocyclic compounds that mainly exist in naturally 
occurring compounds and pharmaceutical products (Figure 12). The 1-azaspiro[4.5]decane skeleton 
is found in cylindricines, lepadiformines, TAN1251 derivatives and lapidilectine B. 38 The 
1-azaspiro[4.4]nonane skeleton was considered as a key intermediate for the total synthesis of 
(±)-cephalotaxine.39 histrionicotoxin and nitraria alkaloids contain azaspiro[5.5]undecane skeletons 
and present valuable biological effects in drug discovery.
Figure 12. Natural occurring products containing azaspirocyclic skeleton
The main challenges for the preparation of spirocyclic motif include the region-controlled and 
stereo-controlled generation of quaternary carbon centers,40 functional group incompatibilities and 
the addition of useful functionality into the newly formed ring system for further synthetic 
manipulation.41 A number of synthetic methods have been described for the construction of 
spirocyclic ring systems. The common synthetic methodologies involve alkylation, rearrangement 
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reactions, ring expansion, metal catalysed cyclisation, radical cyclisation, cycloaddition, ring-closing 
metathesis and the cleavage of bridged ring systems.
2.1 Alkylation and cyclisation
Alkylation provides an efficient way to form carbon-carbon bonds. Intramolecular alkylation to form
the quaternary carbon is the most common method in the preparation of spirocyclic compounds. 
Alkylating agents can displace halide substituents (substitution reaction) or undergo Michael 
additions (1,4-addition) on a tertiary carbon to form a cycle. Xiao’s group reported a one-pot 
reductive bis-alkylation of readily available lactams by organometallic reagents.42 Bis-alkylation of 
lactam 8 with a double Grignard reagent afforded spirocyclic compound 9 in good yield (Scheme 3).
This was also efficient for the formation of the larger ring system 11.
Scheme 3. Bi-alkylation approach to give 1-spirocycles
Iodocyclisation plays an important role in the synthesis of alicyclic and nitrogen-heterocyclic 
compounds, and can be conducted to give high levels of regio- and stereo-selective control. In a 
recent synthesis of the histrionicotoxin analogue 16, the reaction of cyclisation precursor 14, which 
was relatively easily prepared from cyclohexane-1,3-dione in around six steps, with excess iodine 
gave the spirocyclic framework 15 as a single diastereomer (Scheme 4). 43,44 This iodo-derivative 
could then be taken through to the target 16.
8
10 11
9
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Scheme 4. Iodocyslisation in the synthesis of histrionicotoxin analogue
The oxidative spirocyclisation of phenolic primary amines 45 and secondary amines 46 with 
PhI(OAc)2 (DIB) holds considerable potential in the synthesis of spirocyclic natural products such as 
cylindricine C. The DIB-mediated process was developed in the synthesis of spirocyclic compound 
18 (Scheme 5). The major limitation of this approach was the poor yields obtained for 
azaspiro-[5.5]-undecanes.47 This problem could be solved by further research. Cyclisation product 
21 was obtained by bimolecular oxidative amidation of phenol 19, which then underwent 
base-promoted cyclisation to give azaspiro- [5.5]-undecane 21 in 91% yield (Scheme 6).
Scheme 5. Oxidative spirocyclisation
Scheme 6. 1-azaspiro-[5.5]-undecane synthesis
19 20 21
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2.2 Condensation reaction
Intramolecular reactions such as Dieckmann and aldol condensations are useful in the formation of 
five- and six-membered rings. As shown in Scheme 7, spiro-lactam 24 was obtained by a triple 
1,4-addition of nitromethane to methyl acrylate 22 in presence of excess DBU.48 Reduction and 
ester-amide exchange proceeded smoothly to give reduced diester 23. Dieckmann condensation of 
23, followed by basic hydrolysis and decarboxylation then gave the spiro-lactam 24 as an 
intermediate towards a synthesis of the potent immunosuppressant FR-901483(1).
Scheme 7. Dieckmann condensation
The intramolecular aldol condensation was worked in a similar way. The condensation of 29 in the 
presence of potassium carbonate afforded 1-azaspiro[4.4]non-8-en-7-one 30 in 50% yield (Scheme 
8).49
Scheme 8. intramolecular aldol condensation
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2.3 Rearrangement reaction
The rearrangement of the carbon skeleton of a molecular can be used to form a structural isomer of 
the original molecular. Beckmann, Curtius, Claisen, Piancatelli, sigmatropic and Schmidt 
rearrangements have been used in the preparation of azaspirocycles.
The Curtius rearrangement is a classic method of establishing a 3o stereocentre attached to an 
amine-derived functional group.50 In Nagumo’s route, the rearrangement of carboxylic acid 31 and 
N-alkylation were the key steps in the formation of 1-azaspirocyclic compound 37 (Scheme 9).51
The amine group was expected to be more suitable carbamate than for cyclisation. The synthesis 
from cyclohexyl aldehyde was carried out using similar procedures by Liebowitz.52
Scheme 9. Curtius rearrangement and N-lkylation in the synthesis of 1-azaspirocycles.
The acid-induced Beckmann rearrangement of oximes 38 to give spiro-bicyclic lactam 39 was 
reported by Pilli and de Sousa.53 Due to the competitive fragmentation process, the rearrangement 
was proven to be best carried out by treatment of the oxime with tosyl chloride in pyridine at 0oC to 
make the oxime hydroxyl group into a good leaving group (Scheme 10).
31 32 33
34 35 36 37
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Scheme 10. Beckmann rearrangement
Another example of a Beckmann rearrangement was reported by Burnell. Spiro-lactam 41 was 
formed by treatment of carbocyclic spiro-ketone 40 with hydroxylamine-O-sulfonic acid in the 
presence of formic acid (Scheme 11).54
Scheme 11. Beckmann rearrangement
The intramolecular aza-Piancatelli rearrangement provided an efficient pathway to construct the 
tertiary carbon center bearing a nitrogen atom and formation of the spirocyclic ring in a single 
operation. Dysprosium(III) triflate-catalysed aza-Piancatelli rearrangement provided a method for 
the preparation of 1-azaspirocycles (Scheme 12).55 Increasing the size of the R group increased the 
reaction time and resulted in a lower yield of the desired products.
Scheme 12. The intramolecular aza-Piancatelli rearrangement
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A [3.3]-sigmatropic rearrangement is an aliphatic Claisen rearrangement that can generate two 
stereogenic centers and a carbon-carbon double bond. The Yeh group reported a facile synthesis of 
spirocyclic ketones via a cationic allylic vinyl ether gold intermediate.56 The hydroxyl group first 
attacked the gold-activated alkyne and was followed by Claisen rearrangement to give azaspirocycle 
47 (Scheme 13). Due to the difficulty in separating the 1:1 diastereomeric mixture of 47, saturated 
azaspirocycle 48 was obtained by hydrogenation.
Scheme 13. [3.3] Sigmatropic rearrangement
A Prins-Pinacol rearrangement reaction was used as a key step for the construction of 
azaspiro[4.4]nonane (Scheme 14).57
Scheme 14. Prins-Pinacol rearrangement.
Ring-rearrangement metathesis (RRM) has been reported in the synthesis of cyclohexene derivatives. 
The conversion of a cyclic structure into a new cyclic product involves ring-closing and 
ring-opening steps. For the synthesis of nitramine, the major challenge is construction of the 
quaternary carbon center with the correct stereochemistry. In a total synthesis of (±)-nitramine 60, 
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RRM can be an attractive approach to form two contiguous stereogenic centres in one step (Scheme 
15).58
Scheme 15. Ring-rearrangement metathesis
2.4 Cycloaddition
A few examples of cycloaddition have been used in the synthesis of azaspirocycles. A [3+3]-dipolar 
cycloaddition has been used in a formal total synthesis of 12H-HTX (Scheme 16).59
Scheme 16. Dipolar cycloaddition in the synthesis of 12H-HTX.
Based on studies by Grigg and co-workers of a series of inter- and intramolecular aza[3+2] 
cycloadditions,60 Lee and Zhao used a similar cycloaddition reaction to set up the azaspiro core in 
pinnaic acid and halichorine.64 The addition of an oxime 64 to an alkene gave nitrone 65, and then 
intramolecular cycloaddition of the nitrone afforded bicyclic compound 67 (Scheme 17). Spirocycle 
68 was finally obtained via intramolecular Michael addition in overall 40% yield. The 
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stereochemistry can be controlled in this step by the different olefin geometry.
Scheme 17. Intramolecular aza[3+2] cycloadditions
Ketenes were reactive in various cycloaddtions. Snider and Cartaya-Marin demonstrated the utility 
of ketene in the preparation of (±)-nitramine, which was the first alkaloid identified to possess the 
2-azaspiro[5.5]undecane skeleton. In the intramolecular cycloaddition of the nitrone 69, a 
six-membered ring was favoured due to the entropic effects of C-C bond formation (Scheme 18).61
(±)-Nitramine 60 was prepared by hydrogenolysis of 70 with hydrogen over Pd.
Scheme 18. Intramolecular cycloaddition of ketenes.
2.5 Metal-catalysed reactions
Palladium plays an important role in modern chemistry. A large number of reactions in organic 
chemistry can be facilitated by catalysis with palladium compounds.62 Intramolecular ene-type 
cyclisation catalysed by cationic Pd(II) complex was described by Hatano and Mikami in 2003.63
Spirocycles 72 were prepared in good yield and excellent enantioselectivities (Scheme 19). A 
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similar methodology was reported later (2007) by Corkey and Toste (Scheme 20).64 Pd-catalysed 
reactions highlighted have several drawbacks including the use of an expensive catalyst, the need for 
complex starting materials and poor structural diversity.65
Scheme 19. Pd-catalysed synthesis of spirocycles by Hatano and Mikami.
Scheme 20. Pd-catalysed spirocyclisation by Corey and Toste
Samarium(II)-mediated cyclisation of unsaturated keto-lactams to give spirocyclic pyrrolidines and 
piperidines was studied by the Procter group (Scheme 21).66 The substituent on nitrogen in the 
cyclisation substrates had a significant effect on the reaction. The electron-withdrawing group on 
nitrogen was essential for the formation of five-membered rings. Moreover, six-membered 
substrates were more efficiently formed by this approach than the analogous five-membered 
examples.
Scheme 21. Samarium(II)-mediated cyclisation
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Iron complexes are inexpensive and low-toxicity substitutes for the previous metals. FeCl3-promoted 
intramolecular cyclisations have been developed.67 At the alkyne terminus of starting material 77, 
both electro-neutral and electro-deficient arenes were found to be good substrates to give 
(Z)-4-(arylchloromethlene)-substituted azaspirocycles 78 in excellent yields (Scheme 22). The main 
advantage of this approach is that reaction is instantaneous, only one minute was required for the 
reaction.
Scheme 22. FeCl3-promoted cyclisation.
Other metals such as titanium, platinum(II), ytterbium and zirconium have all been used as catalyst 
components for the synthesis of spirocyclic compounds. Ramanathan and Odom described 
titanium-mediated amine allyation of cyclohexylamine by allyl alcohol to prepare the 
1-azaspiro[5.5]undecane.68 Ti(OiPr)4 was used in the intramolecular spirocyclisation of pyridine 
substrates to construct 3,9-diazaspiro[5.5]undecane derivatives.69
2.6 Ring Closing Metathesis
Ring closing metathesis (RCM) was widely used to make various spirocyclic systems with an 
additional double bond in such products to enable further synthetic manipulation. The Edwards 
research group has focused on using tandem RCM reactions of polyolefins to give azaspirocyclic 
compounds in good yield (Scheme 23).70 There were two pathways to form spiropiperidine 81:
conversion of amine 79 into ammonium triflate 80 or trifluoroacetamide 82. Although conversion of 
ammonium triflate 80 into 81 required more catalyst and a longer time, the procedure was 
convenient with no need for hydrogenation. Selective epoxidation reaction was used in the next step 
to prepare histrionicotoxin analogues.
77 78
34
Scheme 23. RCM for histrionicotoxin analogue synthesis
The introduction of two olefinic side chains into lactam 84 would afford various spirocycles by 
means of ring-closing metathesis (RCM). The two-step approach is more flexible than the one-step
approach. Various spiro-cyclic alkenes could be formed with different ring sizes by addition of two 
different alkenyl groups, and the carbon-carbon double bond could be built in different positions for 
further synthetic manipulation. This approach was used in the synthesis of racemic cephalotaxine 87
(Scheme 24).71,72
Scheme 24. The synthesis of (±)-cephalotaxine
The combination of sigmatropic rearrangement and RCM provided a short and efficient route to the 
synthesis of spirocyclic alkaloids such as (±)-perhydrohistrionicotoxin. 73 The rearrangement 
product 89 was formed by treatment of the allylic alcohol 88 with N-(phenylseleno)phthalimide 
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(NPS) and tributylphosphine (Bu3P), followed by exposure to chloramine-T (Scheme 25). The 
alkylation of 89 afforded cyclisation precursor 90 in good yield.
Scheme 25. The combination of sigmatropic rearrangement and RCM approach
A one-pot multicomponent reaction between N-Boc-3-piperidine 92, allylamine, and a boronic ester 
led to cyclisation precursor 93 in toluene at 80oC (Scheme 26). The RCM reaction was processed 
under a standard procedure to form spirocyclic compound 94.74 The addition of p-TsOH was 
essential in the RCM reaction due to the influence of the nucleophilic amino group on Grubbs 
catalyst. This approach was limited to the five-membered ring system.
Scheme 26. One-pot multicomponent reaction.
2.7 Other reactions
Mariano et al. discovered a single electron transfer (SET)-promoted photocyclisation to form the 
spirocyclic amine 97 (Scheme 27).75 Silylarene- iminium salt 96 was the key precursor for the 
cyclisation and was prepared from b-aminoketone 95.
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Scheme 27. Single electron transfer (SET)-promoted photocyclisation
An interesting synthetic approach for the elaboration of 1-azaspiro frameworks was reported by 
Kalaitzakis et al.76 This one-pot process was initiated by singlet oxygen-mediated oxidation of the 
2-substituted furan. The target spirocycle 99 was obtained through an aza-Prins cyclisation (Scheme 
28).
Scheme 28. One-pot synthesis of 1-azaspirocycles by photooxidationof 2-substitued furan
Preparation of spirocyclic derivatives aiming for low-toxic drugs and new drugs via organic 
synthesis has become common practice. Moreover, the efficient routes for the formation of 
spirocyclic structures are highly desired in the development of synthetic methodology. The use of 
such flexible synthetic routes using simple reagents under mild conditions is of great importance.
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Section 3: Application of acid-catalysed cyclisation in the 
Knight group
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3.1 Introduction to acid-catalysed cyclisation
Amines are important chemical intermediates in terms of the synthesis of polymers, pharmaceuticals 
and surfactants, along with many other chemicals. Among the methods used for the formation of 
carbon-nitrogen bonds, hydroamination is one of the most attractive pathways to various 
nitrogen-containing molecules by the addition of amines to alkenes or alkynes. It provides both 
potentially atom-efficient and thermodynamically feasible pathways.77
The hydroamination of alkenes is difficult because of the lower reactivity and electron density of 
carbon-carbon double bonds. For example, in the reaction of 2-methylpropene 100 and ammonia 
101 (Scheme 29), the thermodynamic equilibrium is shifted to the starting materials, and the yield 
decreases with increasing reaction temperature.78 Therefore, a catalyst is required. 
Scheme 29.The amination of 2-methylpropene
Many efforts have been put into the development of efficient and eco-friendly catalysts. Various 
examples are known to be efficient for both inter- and intra-molecular hydroamination of alkenes. 
Metal catalysts play an important role in these reactions. In early studies, hydroaminations were 
mostly triggered by transition-metal catalysts. Compared with late transition metals, early 
transition-metal catalysts such as titanium complexes showed excellent functional group tolerance. 
Gold as a catalyst in hydroamination reactions could work with unactivated olefins to give 
Markovnikov products.79 However, gold cannot be used in reactions of alkylamines or anilines. Due 
to the excellent stereoselectivity obtained using organolanthanide catalysts,80 these have been used 
as highly efficient catalysts for inter- and intramolecular hydroamination and could be used for the 
synthesis of naturally occurring alkaloids. However, lanthanide complexes were limited by lack of
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compatibility with a number of important functional groups. In order to find a cheap and green metal 
catalyst, the scope of the catalyst was expanded by using main-group metals such as Ca81, Bi82, Zn83
as catalysts. 
The disadvantages of metal catalysts include reagent cost, toxicity (Hg, Pd), high air- and 
moisture-sensitivity (lanthanides), high electropositivity (main-group metals) and low 
functional-group tolerance.84 To overcome these problems, it is important to find alternatives to 
such reactions.
In 2002, Schlummer and Hartwig first described the triflic acid-catalysed intramolecular 
hydroamination of tosyl-protected amino olefins in the preparation of pyrrolidines and piperidines 
(Scheme 30). After screening various acids (TfOH, Tf2O, H2SO4, AcOH), they found that an acid 
with a pKa £ 10 was sufficiently acidic to act as catalyst.85 When using concentrated sulfuric acid as 
catalyst, longer reaction times were required.
Scheme 30. Intramolecular hydroamination by Hartwig et al.
In 2005, Bergman et al. reported proton-catalysed hydroamination and hydroarylation reactions of 
aniline and norbornene (Table 1). Both anilinium salts and strong acids were tested in order to find 
an optimal catalyst. Results from experiments suggested that decreasing anion coordination ability 
lead to increase in catalytic efficacy; the coordinating anion NTf2- is stronger than OTf-.86
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Table 1. Acid-catalysed hydroamination and hydroarylation of aniline and norbornene
Catalyst T (oC) t (h) % yielda
PhNH3B(C6H5)4.Et2O 135 27 60
HNTf2 135 27 35
HNTf2 135 48 84
HOTf 135 27 13
a. Combined yield of 107 and 108. 
Bergman et al. also found that the generation of either kinetic or thermodynamic products depended 
on both reaction time and temperature. Products from N-H addition mainly occurred at short 
reaction times, while longer times and higher temperatures are required fro Ar-H addition. It was 
notable that products from hydroamination can be transferred to hydroarylation products in the 
presence of 5-mol% of catalyst (Scheme 31). 
Scheme 31. Conversion of hyrdroamination products to hydroacylation products
In 2006, it was reported that intermolecular additions of phenols and protected amines to the 
unactivated olefins could be catalysed by 1-5% triflic acid in toluene.87 This is an alternative 
method to metal-catalysed reaction to form carbon-oxygen and carbon-nitrogen bonds. In contrast to 
the addition to phenols, hydroamination required a higher reaction temperature (80-85oC). If the 
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concentration of the Brønsted acid and the reaction temperature can be controlled appropriately, the 
intolerance of functional groups could be avoided. The pKa of triflic acid is -15, which places it in 
the super acid class. Experiments shown above indicate that triflic acid can be an effective catalyst 
in hydroamination reactions of alkenes. Optimization of reaction conditions may improve the 
efficiency of using TfOH. 
In acid-catalysed hydroamination cyclizations, the mechanism of intramolecular cyclisation 
probably involves protonation of the tosylamine group and formation of a carbocation by 
intramolecular proton transfer. The resulting carbocation then reacts with the lone pair electron on 
nitrogen to form a ring (Scheme 32). According to Baldwin’s rule, the transformation is an overall 
unfavorable 5-endo-trig cyclisation, but as it involves a carbocation, this is not strictly a mechanism 
to which these rules apply. The basicity of the reacting amine impacts on the reaction rate: more 
basic amines lead to lower reaction rates.88
Scheme 32. Intramolecular proton transfer.
3.2 Application of acid-catalysed hydroamination in the Knight group
Triflic acid-catalysed hydroamination has been a major focus of research in the Knight group and 
has become a straightforward approach for the synthesis of nitrogen-contain heterocycles. The very 
familiar iodocyclisation has been used as a smooth and efficient synthetic method for the preparation 
of pyrrolidines (Scheme 33).89 Haskins in the Knight group found that the overall 5-endo-trig
iodocyclisation of 114 gave only the 2,5-cis isomers 115 when the base was omitted. 
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Scheme 33. Iodocyclisation
The same phenomenon was observed in the synthesis of highly substituted pyrrolidines. In the 
absence of base, however, small amounts of de-iodopyrrolidines 118 were obtained during the 
iodocyclisation process (Scheme 34). The generation of 118 indicated that a direct acid-catalyzed 
cyclisation might be a strategy for this kind of reaction.
Scheme 34. Iodocyclisation 
Acids such as p-toluenesulfonic acid (tosic acid), acetic acid, trifluoroacetic acid, 
trifluoromethanesulfonic acid (triflic acid) were used in initial trials of this acid-catalysed 
hydroamination. Treatment of cyclisation precursor 119 with 0.5 equivalents of tosic acid resulted in 
expected cyclized product 120 (Scheme 35). It indicated that an independent proton source induced 
the same reaction as iodocyclisation.90
Scheme 35. Acid-catalysed cyclisation
When using acetic or trifluoroacetic acids as catalyst, none of the product was obtained. Due to the 
high temperature (70oC) that was essential for tosic acid to work, triflic acid was the reagent of 
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choice for subsequent intramolecular hydroaminations. The standard protocol was to use 0.4 
equivalents of triflic acid in chloroform or dichloromethane at 0oC for around 15 minutes. 
Triflic acid-catalyzed cyclisations were developed as a valuable method for the synthesis of many 
substituted pyrrolidines in Knight group (Figure 13).91 Furthermore, the methodology was extended 
to the synthesis of spiro-pyrrolidines.
Figure 13. Synthesis of substituted pyrrolidines via acid-catalyzed hydroamination
Spiro-pyrrolidine 126 was prepared by treatment of cyclohexane derivative 125 with 0.4 equivalents 
of triflic acid in chloroform at 0 oC (Scheme 36).92 Cyclisation of cyclohexene derivative 127 gave 
the same spiro-cycle 126 under similar conditions. In Haskin’s research, the functionalized 
amino-ester group was found necessary for the acid-catalysed hydroamination to occur. Although the 
N-Ts protecting group was suitable in this approach, detosylation was not efficient.
Scheme 36. TfOH-catalysed cyclisation in spirocycles synthesis
Subsequent work by Henderson in the Knight group tested the ester adjacent to the sulfonamide to 
determine if it was needed for acid-catalysed hydroamination to occur in the synthesis of 
indene-derived spiro-cycles. However, sulfonamides were not successfully cyclized to give the 
desired spiro-cycles; all efforts to preparer spiro-pyrrolidine 128 failed. The sulfonamide was 
considered to be too hindered and might be replaced by a smaller N-protecting group with benefit. 
Moreover, the functionalized amino-ester group might indeed be needed for the formation of 
five-membered ring system.
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For the formation of six-membered ring systems, treatment of cyclohexene derivative 129 with 
triflic acid gave the 6/7 ring system 131 rather than the desired spiro-piperidine 130 (Scheme 37). 
Even though a tertiary carbocation is considered more stable than secondary one, the 7-endo-trig 
cyclisation occurred instead of the expected 6-exo-trig process.
Scheme 37. TfOH-catalysed cyclisation for the formation of 6-membered ring system
Acid-catalyzed hydroamination for the formation of cyclic compounds is of great convenience and 
can be very efficient. However, only a relatively limited range of compounds has been successfully 
synthesized using this method. The preparation of azaspiro[4.5]decane and azaspiro[5.5]undecane 
skeletons by acid-catalysed hydroamination needs to be further investigated. Moreover, the 
preference of the direction of ring closing is not as predictable as in previous experiments. Further 
research is needed.
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Section 4: Acid-catalysed cyclisation in targeted synthesis
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4.1 Synthetic hypothesis
The synthetic plan for the present project was based purely on identifying ways in which a 
spiro-piperidine could be synthesized using our recently discovered acid-catalysed methodology for 
the synthesis of saturated N-heterocycles. Given this idea, then the initial aims can be summarized 
by the following Scheme:
Scheme 38. Synthetic plan for spiro-cyclic compound synthesis
Based on our reported findings concerning such cyclisations, the initial target, the spiro-piperidine 
132 should be generated by trapping of the carbenium ion 133 by the pendant protected amino group 
in the side chain. In principle, there are three suitable precursors to this carbenium ion: the 
exo-alkene 134, the tertiary alcohol 135, and the endo-alkene 136, by exposure to strongly acidic 
conditions.
The polarity inversion of a carbonyl group was thought to be an efficient way to form spirocyclic 
compounds containing a functional carbonyl group. 2-Substitutied-1,3-dithianes (137 and 142) will 
be formed under known procedures by reaction of carbamates and 1,3-propanedithiol followed by 
alkylation. If the preparation of ketones (139 and 144) is successful, combined with experimented 
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successful synthetic pathways shown on Scheme 37, the formation of bis-spiro-cyclic compound 
141 and tris-spiro-cyclic compound 146 could be possible (Scheme 39).
Scheme 39. Initial routes for spiro-cyclic compound synthesis
4.2 Results and discussion
4.2.1 Preparation of 1,9-diazaspiro[5,5]undecane
4.2.1.1 Wittig reaction
The Wittig reaction is widely used in organic synthesis for the preparation of alkenes and commonly 
used to couple aldehydes or ketones to singly substituted phosphine ylides. Generally, the geometry 
of the resulting alkene depends on the ylide: simple phosphoranes are unstable and very reactive and 
tend to lead to (Z)-alkenes, while (E)-alkenes will usually be formed from stabilized ylides (Scheme 
40).
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Scheme 40. Wittig reaction mechanism
An initial attempt was made to prepare the 1,9-azaspiro[5.5]undecane skeleton using such a Wittig 
reaction (Scheme 41). Nitrogen-protected 4-piperdione 149 was prepared using a reported method93
and expected to be reactive due to its wide use as an important intermediate in the chemical and 
pharmaceutical industry. For example, N-benzyl-4-piperidone is used to make Pimozide and 
Benperidol, and N-methyl-4-piperidone was used to make Dorastine.
Scheme 41. Synthesis of 1-tosylpiperidin-4-one
The Wittig addition of 1-tosylpiperidin-4-one 149 to the ylide derived from phosphonium salt 150
was carried out using the previously reported procedure (Scheme 42).94 The ylide was generated by 
adding a solution of phosphonium salt 150 to 2.2 equivalents of potassium bis(trimethylsilyl)amide 
(KHMDS). After 15 minutes at room temperature, a solution of the ketone 149 was added to the 
resulting bright red solution and the mixture was stirred at room temperature. After 3 hours, the 
reaction was quenched with water. The water layer was extracted with ether and acidified with 10% 
HCl to pH 2 and re-extracted. 
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Scheme 42. Reagents and conditions: KHMDS, THF, r.t, 3h.
NMR analysis of the crude product showed the product was mainly unreacted 1-tosylpiperidin-4-one 
149. Only a trace of alkene product could be seen from the NMR spectrum, which was present 
around 5.0-5.3 ppm. Leaving the reaction mixture overnight also resulted in none of expected 
compound being obtained. However, later repeats of this reaction (Scheme 58) did indeed produce 
the desired acid.
The stablized ylide 152 is easy to prepare, but obviously is less reactive than an unstablised ylide. 
The Wittig reaction of methyl (triphenylphosphoranylidene) acetate 152 and piperidone 149 was 
tried under similar reaction conditions (Scheme 43). Unfortunately, none of the desired product 153
was obtained. 
Scheme 43. Reagents and conditions: THF, r.t, 3h.
The unstable and quite reactive zwitterionic intermediate ylide might be a reason for the 
unsuccessful Wittig reaction. The active zwitterion could instead act as a base, hence preventing 
condensation as the ketone would be enolized.
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A slightly different approach to the Wittig reaction, a Horner-Wadsworth-Emmons (HWE) reaction 
is another phosphorus-mediated reaction to form alkenes. Compared with phosphonium ylides in 
Wittig reactions, phosphonate-stabilized carbanions in HWE reactions are more nucleophilic and can 
react with a wider variety of ketones (Scheme 44).95
Scheme 44. Horner-Wadsworth-Emmons (HWE) Olefination
The HWE reaction could be an alternative method for the failed Wittig reaction in our case. Sodium 
hydride (60% dispersion in mineral oil) was used to form an a-metalated phosphonate. Nucleophilic 
addition of deprotonated 154 onto the 4-piperidone 149 (Scheme 45) did not give the desired 
exo-alkene 155. 
Scheme 45. Reagents and conditions: NaH, THF, r.t, 3h
Alternatively, another approach to effect such a homologation could be by treatment of 4-piperidone 
149 with Grignard reagents, which was attempted. The addition of 1.5 equivalents of 
vinylmagnesium bromide to 1 equivalent 4-piperdidone led to alcohol 156 in moderate yield 
(Scheme 46). Increasing reaction temperature to 25-30oC, the product yield was improved and the 
crude product can be used directly to next step without any purification. However, only trace 
amounts of the desired bromide 157 were detected after bromination with PBr3. 
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Scheme 46. Reagents and conditions: i. CH2CHMgBr, 25oC, 16h; ii. PBr3, r.t, 16h.
The unreactive properties of the 4-piperidone were in good agreement with the observations made 
by Reddy who found that either Wittig reaction and HWE reactions of N-subtituded-4-piperidone 
158 did not provide the expected product 159 under a diverse range of conditions (Scheme 47).96
The decomposition of the phosphonate and Wittig reagents was found rather than the expected 
product. We still do not know the reason why such piperidones were not reactive in these 
phosphorus-mediated reactions.
Scheme 47. Attempted synthesis of piperidine building block under diverse conditions.
4.2.1.3 Alkynylation
Direct addition of alkynes to carbonyl groups provides a way of C-C bond formation, which has 
been widely used in the preparation of propargyl alcohols. The alkoxide is first formed by 
nucleophilic addition of acetylides to carbonyl compounds, protonation of which gives propargyl 
alcohols (Scheme 48). Strong bases such as n-butyllithium (BuLi), lithium diisopropylamide (LDA), 
potassium hexamethyldisilylamide (KHMDS), sodium hydride (NaH), and potassium hydride (KH) 
are often used to remove protons from terminal alkynes.
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Scheme 48. Preparation of propargyl alcohols.
An addition of a terminal alkene to a ketone would provide access to propargyl alcohols. Similar 
experiments have been reported in the literature. A catalysed alkynylation of various terminal 
alkynes and cyclohexanone was reported by Ishikawa et al. The reaction of diverse ketones and 
alkynes using benzyl trimethylammonium hydroxide as base smoothly proceeded to give the 
corresponding propargylic alcohols in good yields (Table 2).97 Hence, such an addition of an alkyne 
to a ketone can be a useful way to introduce an alkyl group. The reaction of 1-hexyne with 
cyclohexanone required a longer reaction time (20h) to result in a low yield of product (43%), in 
contrast to the reaction of alkynes containing benzyl ether group. Aromatic alkynes may be more 
suitable in these reactions.
Table 2. Examples of addition of alkynes to aliphatic ketones
Entry Ketone Alkyne Methoda Time / hrs Yield / %
1 A 2 95
2 A 20 43
3 A 12 84
a Method A: To a solution of alkyne (5.0 mmol) and ketone (1.2 eq.) in DMSO (2.5 mL) was added a solution of 
catalyst (10 mol %) in DMSO (2.5 mL) over 10 min at r.t; 
In absence of catalysts, a nucleophilic addition of 4-(tosyloxy)but-1-yne and carbonyl compounds 
was reported by Mukai et al..98 The yields of propargylic alcohols were quite low, especially when a 
symmetrical ketone was used (Table 3). 
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Table 3. Nucleophilic addition of terminal alkynes to ketones
Direct addition of terminal alkynes to 4-piperidone could therefore be an attractive method to 
prepare the 1,9-diazasoiro[5.5]undecane skeleton. The alkyne is first deprotonated followed by 
addition of the resulting nucleophiles to the carbonyl group give the propargyl alcohol, then 
hydrogenation and cyclisation could produce the desired spiro-piperidine. If this approach is 
successful, it will be an efficient way to produce spiro-piperidines.
A co-solvent such as DMPU might be necessary to this kind of reaction to promote the solubility of 
reagents and accelerate the reaction rate. Treatment of 4-piperidone 149 with the terminal alkyne 
160 in the absence of DMPU afforded the unexpected product 161 (Scheme 49). Evidently, NMR
analysis of the crude product showed no terminal alkyne protons around 2 ppm. Butyl lithium (BuLi) 
had attacked the ketone faster than the alkyne at room temperature and resulted in the formation of 
undesired alkylation product.
Scheme 49. Reagents and conditions: i, BuLi, THF, 0 oC – -78 oC – r.t; 15.8%
A solution of 2.1 equivalents of BuLi and 1.1 equivalents of alkyne 160 in THF was stirred at -40oC 
for 2h then cooled down to -78oC. 4 equivalents of DMPU were added dropwise and the resulting 
solution was stirred for a further 1h. Piperidone 149 in THF was then added dropwise. The reaction 
R1 R2 Yield (%)
H Me 54
H Bu 48
Me Me 44
160149 161
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mixture was stirred at -78oC for 4h, followed by warming slowing to -20oC and stirring overnight. 
Aqueous ammonium chloride was added to quench the reaction, which was then extracted. 1H NMR 
data showed that none of the desired new product was formed (Scheme 50). 
Scheme 50. Reagents and conditions: i, n-BuLi, DMPU, THF, -20 oC, overnight.
The O-tosyl protected alkyne was also tried. Considering the possible deprotonation of the mesyl 
group in mesylated alkene with BuLi, the alternative base, LDA, was used. Unfortunately, no 
reaction occurred even after leaving the reaction for 48h. Mesylate is a good leaving group; it is 
possible to form a compound containing two triple bonds, which might be hard to identify from the 
1H NMR spectrum of crude product (Scheme 51). 
Scheme 51. Possibility of formation of 165.
An addition of the N-tosylated alkyne to piperidone gave a small amount of expected product
(Scheme 52). 1H NMR analysis of the product isolated from silica gel column chromatography
showed that no starting ketone was presented, and new peaks at 2.0, 2.4 and 3.3 ppm for the
piperidone were found. Moreover, two different shifts for the tosyl group could be seen between 
7.2-7.8 ppm. Increasing amount of DMPU, increasing reaction temperature, changing solvent had no 
positive effect on the reaction, and mainly starting materials were present. 
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Scheme 52. Reagents and conditions: i. n-BuLi, DMPU, THF, -20 oC, overnight.
4.2.2 Preparation of 1-azaspiro[5.5]undecane
4.2.2.1 Modified-Julia Olefination
The classic Julia olefination comprises of the addition of a lithiated sulfone to a carbonyl group, with 
the formation of a b-hydroxy or derived acyloxy sulfone and elimination. The disadvantages of the 
classic Julia olefination include low tolerance of reducible functional groups and reversible 
processes in the reaction between the sulfone anion and the ketone.99
The modified Julia olefination gives the olefin directly by replacement of phenylsulfone with 
heteroaryl sulfones. Benzothiazolyl (BT) sulfone is widely used, comparing with other heteroaryl 
sulfones such as pyridin-2-yl (PYR), 1-phenyl-1H-tetrazol-5-yl (PT), 1-tert-butyl-1H-tetrazol-5-yl 
(TBT) or 3,5-bis(trifluoromethyl)phenyl (BTFP) sulfone (Figure 14). However, for sterically 
unencumbered sulfones such as methyl BT-sulfone, self-condensation cannot be avoided due to its 
donor-acceptor nature.100 Self-condensation of BT-sulfone has been improved by using Barbier 
conditions.101
Figure 14. Heteroaryl sulfones for the modified Julia olefination
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The first step of modified Julia olefination is the same as in its original form and involves the 
addition of metalated BT-sulfone to a carbonyl group (Scheme 53). The resulting b-alkoxysulfone 
experiences a facile rearrangement and results in formation of a sulfinate salt. Alkenes will be 
produced directly by spontaneous elimination of sulfur dioxide and lithium benzothiazolone.
Scheme 53. Mechanism of modified Julia olefination.
A preparation of the desired BT-sulfone 172 for the modified Julia olefination was first tried starting 
from 4-amino-1 butanol, in three steps (Scheme 54). The commercially available 4-amino-1-butanol 
168 was first protected as the corresponding carbamate 169 by using 1.1 equivalents of methyl 
chloroformate in the presence of triethylamine (Et3N). The resulting carbamate was found to be 
water-soluble and its isolation resulted in a low yield. The work-up procedure could be optimized by 
evaporating the reaction solvent straight away and eluting the subsequent chromatography column 
with 2% methanol in dichloromethane, after the reaction was completed.
Scheme 54. Reagents and conditions: i, ClCO2Me, DCM, 0oC®r.t., 4h; ii, BTSH, DIAD, Ph3P, THF, 0oC®r.t., 24h; iii, 
Na2WO4.2H2O-H2O2.
168 169 170 171
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The Mitsunobu reaction allows for facile change of functionality of the hydroxyl group to thioether 
via a nucleophilic displacement. Azodicarboxylic acid esters such as diethyl azodicarboxylate 
(DEAD) or diisopropyl azodicarboxylate (DIAD) are used as oxidants of triphenylphosphine to 
triphenylphosphine oxide. 1.5 Equivalents of DIAD were added slowly to a solution of alcohol 169, 
triphenylphosphine and BTSH at 0oC. After 4h, none of desired thioether product was obtained. 
Increasing the amount of BTSH to 2.2 equivalents and increasing the reaction temperature to 40oC, 
gave only 3% desired BT-sulfide 170. The combination of sodium tungstate dihydrate and 30% 
aqueous hydrogen peroxide was used as oxidant in preparation of the Julia olefination precursor 
BT-sulfone171. Less than 2% of the expected product was generated after purification. 
Considering the possible influence of the carbamate on the Mitsunobu reaction, tosylated amine 172, 
and phthalimide 174 were tried under the same conditions. Unfortunately, none of the desired 
products were obtained (Scheme 55). 
Scheme 55. Failed Mitsunobu reactions
The Ph3P-DIAD system is generally useful for acidic nucleophiles with pKa < 11.102 In our case, 
more active coupling agents may be needed. Moreover, Mitsunobu reactions may be more suitable 
for secondary alcohols than primary alcohols in these examples.
Alternatively, BT-sulfones can be prepared using standard substitution procedures (Scheme 56). 
Using an excess amount of triethylamine was effective for the mesylation: 5 equivalents of 
triethylamine produced a higher yield of the mesylated product 176 than using 2.3 equivalents; the 
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yields were 98% and 70% respectively. The substitution of carbamate with BTSH proceeded in 
dichloromethane in the presence of triethylamine as base. The desired BT-sulfide 170 was produced 
in very low yield and the 1H NMR spectrum showed that the products were mainly unreacted 
starting material BTSH. The reaction was tried using different combinations of base and solvents but 
all attempts to improve the yields of the substituted products were ineffective.
Scheme 56. Reagents and conditions: i, MsCl, Et3N, DCM, 0oC, 1h; ii, BTSH, Et3N, DCM, r.t., overnight.
In the preparation of BT-sulfone derivatives using reported literature methods (Scheme 57),103,104
the reaction was found not to be affected by an increase of the size of the alkyl chains of substrates. 
However, the alkyl chains terminated by polar functional groups had a deleterious influence on the 
substitution. 
Scheme 57. preparation of BT-sulfone derivatives
The influence of terminal functional groups existed in our case. In the absence of the protected 
amine group, the reaction of bromide 180 proceeded smoothly with two equivalents of triethylamine 
and produced the BT-sulfone 181in 76% yield (Scheme 58). 
Scheme 58. Reagents and conditions: i, BTSH, Et3N, DCM, r.t., overnight.
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The synthesis of the required BT-sulfone intermediates was not achieved. The reaction time for 
S-alkylation and S-oxidation was long and the yields were very low. Oxidation of the thioether 
resulted in isolation of a residue that was deemed beyond purification. The synthetic route outlined 
above (Schemes 53 and 55) could possibly be successful if the amine group could be introduced in a 
later step or by starting from a secondary alcohol. 
The selectivity for BT-sulfones was highly dependent on the choice of base and the exact reaction 
conditions. Chatterjee et al. reported the Julia-Kocienski olefination afforded the highest yield (68%) 
by using KHMD as base and Et2O as solvent at -78oC, while no product was produced in presence of 
NaHMD in THF at -78oC.105 Considering the relatively low yield in the preparation of trisubstituted 
olefines (29%-33%) in the reported literature.106 we returned to the use of Wittig reactions to 
construct the required trisubstituted olefins, but using cyclohexanone as a simpler model ketone. 
4.2.2.2 Wittig Olefination
The Wittig reagent 4-carboxybutyltriphenylphosphonium bromide is commercially available. The 
Wittig reaction proceeded smoothly with potassium bis(trimethylsilyl)amide in anhydrous THF 
(Scheme 59). In our case, only one isomer could be obtained via a Wittig reaction. The NMR 
spectrum of the crude product shown peaks for the alkene proton at around 5 ppm.
Scheme 59. Reagents and conditions: i. KHMDS, THF, r.t, 3h; 
The carboxylic acid 184 could be easily converted into the corresponding carbamate via a Curtius 
rearrangement. The mechanism of Curtius rearrangement is a concerted mechanism with the 
formation of an acyl nitrene and isocyanate happening together (Scheme 60). The formed isocyanate
can be used to react with alcohols to generate a carbamate, or be hydrolysed to give a primary amine, 
or react with amines to form urea derivatives. 
 
183182
60
Scheme 60. Mechanism of Curtius rearrangement.
In our case, carbamate was prepared by the adding of methanol to introduce the methoxy group.
Zinc chloride (ZnCl2) was expected to work better than copper(II) chloride (CuCl2) as the latter is a 
weak Lewis acid (Scheme 61). However, results from our experiments showed that both ZnCl2 and 
CuCl2 are not efficient catalysts.
Scheme 61. Reagents and conditions: i. DPPA, Et3N, CuCl2, CH3OH, toluene, reflex, 2h.
4.2.2.3 Cyclisation
A brand new bottle of triflic acid was used as catalyst in the attempted intramolecular 
hydroamination of the amino-alkene. Following some standard procedures for acid-catalyzed 
hydroamination, treatment of the amino-alkene with 0.5 equivalent of triflic acid in dichloromethane 
at room temperature could give cyclised product. 
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There are two possibilities to form a carbenium ion by protonation: a secondary carbenium ion and 
tertiary carbenium ion (Scheme 62). If the secondary carbenium ion 187 were formed, cyclisation 
would occur though an overall 5-exo-trig process leading to the unwanted pyrrolidine 188. As was 
expected, if the tertiary carbenium ion 185 were to be formed, the desired spiro-piperidine 186
would be obtained via an overall 6-endo cyclisation. 
Scheme 62. Two pathways to form carbenium ion and cyclisation
Compound 186 would most likely form carbenium ion 185 as this would be more stable than 
secondary carbocation 187. The cyclisation of 184 was carried out at room temperature for 30 
minutes and showed formation of the product 188 rather than of 186. The most obvious distinction 
of these two compounds would be visible in their 1H spectra. A poorly resolved quartet was present 
around 3.1 ppm, which could be attributable to the proton on C-5. A notable peak was present at 2.5
ppm (C-6) as a doublet of triplets. Those two notable peaks should belong to new compound 188. 
This was further confirmed by 13C spectroscopy. The quaternary carbon expected for the 
spiro-piperidine 186 was not present. Instead, two CH signals in pyrrolidine 188 were present at 41
ppm (C-6) and 58.9 ppm (C-5).
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Although both 5-exo-trig and 6-endo-trig processes are favored, the secondary carbocation was more 
challenging to form than the tertiary one. It was therefore very surprising that pyrrolidine 188 was 
formed instead of the expected spiro-piperidine 186. Maybe the stabilization afforded by the 
cyclohexyl group was insufficient to enable formation of the tertiary carbenium ion 185, resulting in
the formation of pyrrolidine 188. More likely, however, is the influence of some steric factors, which 
make the hoped-for spiro-piperidine more difficult to access. 
Studies into intramolecular acid-catalysed hydroamination of amino-alkenes in the Knight group, 
conducted by Haskins and Henderson, showed that the formation of the five-membered ring 
products was favoured, which were highly sterically crowded. The overall 6-endo-trig process was 
favoured kinetically to give the piperidine 191 in the cyclisations of this and related hydroxylamines, 
but this then rapidly isomerized to the more stable pyrrolidine 190. Only small amounts of the 
piperidine 191 were ever isolated from such cyclisations (Scheme 63).107
Scheme 63. Acid-catalyzed cyclization of amino-alkene
The failure to synthesize spiro-piperidine 186 from carbamate 185 suggests that further investigation 
of this acid-catalysed hydroamination via a 6-endo-trig process is required. According to Baldwin’s 
rules in cyclisation, both 5-exo-trig and 6-endo-trig processes are favored. Results from previous 
experiments suggested that 5-exo-trig is more favored in our acid-catalyzed cyclisation system. 
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Moreover, a small amount of product from the 6-endo-trig process can be isolated from cyclisation, 
which indicated ring opening and ring closing processes may exist. Reaction conditions may be 
optimized to prevent these ring opening and ring closing processes in future work.
4.2.3 Preparation of 2-substituted-1,3-dithiane derivatives 
The controlled formation of carbon-carbon bonds is a critical step in organic synthesis. Organosulfur 
carbanions have been proven to be useful in C-C bond formation. As a temporary reversal of the 
functional group polarity, 1, 3-dithiane derivatives have been widely used in the total synthesis of 
natural products. 2-Substituted-1,3-dithiane derivatives can be easily prepared by deprotonation with 
alkyl lithiums of the corresponding dithiane (Scheme 64). The corresponding ketone will be 
obtained by reaction with an electrophile. 
Scheme 64. Polarity inversion of a carbonyl group.
2-Lithio-1,3-dithiane derivatives were considered to be amongst the most successful 
sulfur-stabalised acyl anions due to the effect of the sulfur atoms on the adjacent carbanions by 
electron back-donation into vacant sulfur d-orbitals.108,109 Due to the highly nucleophilic nature of 
dithiane anions, many electrophiles react smoothly with them, although obviously sites where 
reactions are not required need protection.
In the synthesis of compound 194, it was found that trans-metalation at the 2-position of the dithiane 
193 occurred rapidly at low temperature and this process is faster than direct metalation, allowing 
for the smooth introduction of the two substituent chains (Scheme 65).110
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Scheme 65. Transmetalation of 2-substitutied-1, 3-dithiane
Preparation of the desired 2-substitutied-1,3-dithiane 197 followed the standard procedure: treatment 
of carbamate 196 with 1,3-propanedithiol and boron trifluoride diethyl etherate gave 197 in an 
excellent yield (Scheme 66).112
Scheme 66. Reagents and conditions: i. Et3N, ClCO2CH3, DCM, r.t, overnight; ii. HS(CH2)3SH, BF3.O(C2H5)2, 0oC, 6h.
In our targeted synthesis, 1,3-dithiane derivatives can potentially be used to form cyclisation 
precursors by such substitutions. The resulting 2-substituted-1,3-dithiane derivatives could then 
undergo acid-catalysed hydroaminations to arrive at the targeted spirocyclic compounds having a 1, 
3-dithiane group, which could subsequently be hydrolysed to reveal the corresponding ketone group.
In a model study, Grignard reagent addition of vinylmagnesium chloride to cyclohexanone gave the 
product 198 (Scheme 67), which was directly used in the next step without purification. Treatment 
of alcohol 198 with PBr3 yielded only 23% of the bromide 199. Both the Grignard and bromination 
products turned out to be highly sensitive compounds.  Alternatively, chlorination of alcohol 198
with 1.5 equivalents of acetyl chloride 200 gave the more stable chloride 201 in excellent yield 
(Scheme 68).
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Scheme 67. Reagents and conditions: i. CH2CHMgBr, THF, r.t., 12h; ii. PBr3
Scheme 68. Reagents and conditions: i. 1.5 AcCl, CH3OH, CH2Cl2, r.t., 2h.
Generally, 1,3-dithianes can be metallated with n-BuLi (pKa ³ 45) and the resulting anions are 
sufficiently stable and reactive to serve as nucleophiles in carbon-carbon bond formation. The pKa 
of carbamate is approximately 17, whereas the pKa of 1,3-dithianes ranges from 30 to 35. n-BuLi is 
therefore a suitable choice of base in the next step.
The substitution reaction of the bromide 199 and 1,3-dithiane derivatives 197 provided the product 
202 instead of the expected product 142 (Scheme 69): the substitution reaction of the allylic bromide 
with 199 occurred on the amine, which was both surprising and disappointing. From the 1H NMR 
spectrum of 202, a notable triplet at 4.0 ppm indicated that substitution did not occur on the dithiane.
A board singlet peak for NH was not visible. An alkene proton was observed around 5.0 ppm.
Scheme 69. Reagents and conditions: i. n-BuLi, dithiane X, DMPU, -78oC to -20oC, overnight in freezer.
The substitution of 1,3-dithiane 197 with simple bromide 203 was tried under the same reaction 
conditions. Unfortunately, none of desired compound 137 was obtained but rather compound 204
(Scheme 70). 
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Scheme 70. i. n-BuLi, dithiane X, DMPU, -78oC to -20oC, overnight in freezer.
From 1H NMR analysis of compound 204, which was similar to compound 202, a singlet peak at 5.1
ppm was assigned to the alkene. Moreover, a triplet at 4.0 ppm showed that the 1,3-dithiane starting 
material had not been substituted. It is notable that there are two double doublets between 3.5-4.0 
ppm, which could correspond to the two protons adjacent to a nitrogen (Figure 15). The two methyl 
groups appear as just one singlet peak at 1.7 ppm. The product might therefore be 204. 
Figure 15. Two protons beside nitrogen in compound 204
The compound generated from substitution of 1,3-dithiane was treated with triflic acid to prove the 
proposed structure. If building block 137 had been successfully prepared, and the foregoing 
conclusion incorrect, cyclisation of 137 with triflic acid should give the piperidine 138 (Scheme 71).
Scheme 71. Cyclisation
If carbamate 204 was formed from substitution of 1,3-dithianes, as we think is the case, a tertiary 
carbocation 205 will be formed when treated with triflic acid. To our surprise, the tertiary triflate 206
was isolated, thereby confirming the foregoing assignments (Scheme 72). 
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Scheme 72. Cyclisation 
The formation of compound 206 could be confirmed by 1H NMR spectroscopy. First of all, a clear 
triplet presenting at 2.7 ppm indicated the alkene had been converted into an alkane. Secondly, a 
characteristic resonance of a trifluoromethyl group of 205 can be found in the carbon NMR 
spectrum, with four resonances appearing around 120 ppm. According to the Aldrich NMR library 
database, the 13C NMR resonances for a trifluoromethyl group are present at 125 ppm, 121 ppm, 117 
ppm and 112 ppm. Thirdly, one quaternary carbon for C-OTf in 205 was visible at 91 ppm. 
A similar experimental procedure was found in a reported literature. All attempts to carry out the 
reaction of lithiated dithiane 207 with 3-chloro-2-(trimethylsiloxy)-1-propene 208 were 
unsuccessful.111 The authors concluded that more reactive electrophiles might be required for the 
condensation of the lithiated dithiane (Scheme 73).
Scheme 73. Reaction of lithiated dithiane with 3-chloro-2-(trimethylsiloxy)-1-propene
4.3 Conclusions and future work
An initial attempt was made to apply acid-hydroamination in synthesis of bis-piperidone failed. A 
large amount of time was dedicated to form the exo-alkene starting from N-tosylated piperidone. 
After the failed synthesis of BT-sulfones using the modified Julia olefination to generate the 
amino-alkene, alternative Wittig reaction and HWE reaction were also tried but only starting 
material could be recovered. The starting material N-tosylated piperidone was surprising unreactive.
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In the preparation of propargylic alcohols (Scheme 74), even though a disappearance of starting 
material was observed during attempted alkynylation, only a small amount of desired compound was 
isolated. Various terminal alkynes were tried but failed to give any of the expected products. 
Different bases and solvents need to be tried in future work to promote such additions of alkynes.
Scheme 74. Preparation of propargylic alcohols
Cyclohexanone was used to replace 4-piperidone to investigate acid-catalysed hydroamination in 
spiro-cyclic compound synthesis. The carboxylic acid was prepared by a Wittig reaction in high 
yield, but conversion of the carboxylic acid to a carbamate via Curtius arrangement only afford less 
than 10% isolated product. DPPA is known to be unstable and it was difficult to purify the target
product from the phosphorus residues. Sodium azide may be worth investigating in further 
experiments, and Lewis acids such as Zn(OTf)2, ZnCl2, CuCl2, and AgOTf could also be effective.
In the cyclisations of the exo-alkene 184, we have discovered that although the tertiary carbocation
was more stable than the secondary carbocation, it was more challenging to obtain. It is proposed 
that triflic acid might process ring opening and ring-closing via equilibrating carbenium ions in the
presence of strong acid to form the pyrrolidine 188 instead of spiro-piperidine 186 (Scheme 75). 
This problem was encountered in previous research in the Knight group. 
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Scheme 75. Equilibrating carbenium ions of amino-alkene
In studies into the substituition reaction of bromides and 2-substitued 1,3-dithianes, a lot of effort 
was dedicated towards identifying the product from the substitution reaction. Metalation of 
1,3-dithianes with n-BuLi may not be complete (Scheme 76). Further investigation into the synthesis 
of 1,3-dithianes bearing different protecting groups is needed.
Scheme 76. Metallation of 1,3-dithianes with base
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Section 5: Experimental Section
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5.1 General Details
All non-aqueous reactions were performed using oven-dried glassware and under an atmosphere of 
dry nitrogen. Unless otherwise stated, reactions were stirred magnetically. Heated reactions were 
conducted in a stirred oil bath heated on a hotplate. Reactions conducted at “0°C” were cooled using 
an ice-water bath. Reactions conducted at “-20°C” were cooled using an ice-sodium chloride bath. 
Reactions conducted at “-78°C” were cooled using an acetone-solid carbon dioxide bath. 
“Evaporated” refers to solvent removal using a Buchi rotary evaporator with water pump vacuum 
and water bath at ambient temperature.
Dry tetrahydrofuran (THF) was obtained by fresh distillation from sodium wire and benzophenone. 
Dry dichloromethane (DCM) was obtained by fresh distillation from calcium hydride. All other dry 
solvents were obtained commercially from Fisher Scientific Ltd.
Silica gel chromatography and filtration were performed using Matrex Silica (35-70 µm). All 
reactions were monitored by TLC, using Merck silica gel 60 F254 pre-coated aluminium-backed 
plates and were visualised using ultraviolet light and potassium permanganate. All melting points 
were determined on a Kofler hot-stage apparatus and are uncorrected. Infrared (IR) spectra were 
obtained using a Perkin Elmer 1600 series Fourier Transform Infrared Spectrometer, as a solution in 
dichloromethane (DCM). NMR spectra were recorded on a Bruker DPX 400 instrument with proton 
(1H) NMR spectra recorded at 400 MHz. 13C spectra recorded at 125 MHz were obtained using a 
Bruker DPX500 instrument. Unless otherwise stated, spectra were obtained from dilute solutions in 
deuteriochloroform (Chloroform d; CDCl3) and at 298 K. Abbreviations used for the multiplicities 
are: singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), septet (sept.), unresolved multiplet 
(m). Apparent (app.) refers to overlapping peaks appearing to display a given multiplicity. Mass 
spectra were recorded on a Fisons VG Platform II Mass Spectrometer using atmosphere pressure 
chemical ionization [APCI].
As this was planned to be an extended model study, many of the products have only been 
characterized by proton NMR data.
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5.2 Experimental data
1-Tosylpiperidin-4-one 149
p-Toluenesulfonyl chloride (7.53 g, 39 mmol) was added to a slurry of potassium carbonate (8.90 g, 
64 mmol) and 4-piperidone monohydrate hydrochloride 147 (3.80 g, 25 mmol) in water (30 mL) and 
CH2Cl2 (30 mL). The reaction mixture was vigorously stirred overnight at room temperature. 
Saturated aqueous sodium bicarbonate solution was added to quench the reaction. The organic and 
aqueous layers were separated and the aqueous layer was extracted with dichloromethane (3 x 40 
mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to give the
title compound 149 as a colourless solid (8.25 g; 84%). The crude material was purified by 
recrystallization from petrol/DCM (10:2) and showed m.p. 280-283oC. 1H NMR (400 MHz / CDCl3) 
d: 7.2-7.6 (m, 4H, TsCH), 3.2 (t, 4H, J = 6.2 Hz, 2 x CH2N), 2.40 (app. t, 4H, J = 6.2 Hz, 2 x 
COCH2) and 2.30 (s, 3H, Ts CH3). LRMS m/z calcd. for C12H15NO3S [M]+ = 253; found: 253.
N-(Methoxycarbonyl)-3-butynylamine 160
To a stirred mixture of 4-pentynoic acid (1.04 g, 10.6 mmol), toluene (15 mL) and triethylamine 
(1.48 mL, 1.08 g, 10.6 mmol). Diphenylphosphoryl azide (2.28 mL, 2.92 g, 10.6 mmol) was added 
via syringe over 2 min, and the resulting solution heated at 80oC for 2h until bubbling ceased. The 
oil bath was cooled to 50oC and methanol (4.4 mL, 102 mmol) was added. The resulting reaction 
149147
160
73
mixture was stirred at 50oC for 14h and then allowed to cool down to room temperature. The toluene 
and methanol was removed by rotary evaporation at room temperature. The resulting yellow oily 
residue was diluted with 20 mL of Et2O, 10 mL of water and 2 mL of saturated aqueous sodium 
carbonate. The aqueous layer was separated and extracted with ten 10-mL portions of Et2O, and the 
combined organic layers were washed with 40 mL of brine, dried over MgSO4, filtered and 
concentrated to give the title compound 160 as a yellow oil. The crude compound was purified by 
column chromatography (silica gel, petroleum ether/ethyl acetate = 10:1) to afford the pure product 
as a pale yellow oil, 1H NMR (400 MHz / CDCl3) d: 5.46 (app. br s, 1H, NH), 3.60 (s, 3H, CO2CH3), 
3.21 (app q, 2H, J = 6.4 Hz, NHCH2), 2.40 (dt, 2H, J = 2.6, 9.1Hz, 3-CH2) and 2.00 (t, 1H, J = 2.6 Hz, 
alkyne-CH). 
4-Butyl-1-tosylpiperidin-4-ol 161
The carbamate 160 (0.267 g, 2.1 mmol, 1.0 eq.) was dissolved in dry THF (5 ml) under N2 and the 
solution cooled to 0oC for 5 minutes. BuLi (2.5M in hexane, 0.15 ml, 2.02 mmol, 2.1 eq.) was then 
added dropwise then the temperature was maintained at 0 oC for 30 minutes, then cooled down to 
-78oC. Piperidone 149 (0.243 g, 0.96 mmol, 1.0 eq.) in THF (5 ml) was then added. The reaction 
mixture was allowed to warm to room temperature and stirred overnight. Saturated aqueous 
ammonium chloride (1 ml) was added into the reaction mixture, which was then evaporated. The 
residue was partitioned between water (10 ml) and dichloromethane (20 ml) and the separated 
organic layer dried over MgSO4, filtered and evaporated to give the title compound 161 as a light 
yellow oil (0.053 g, 16%); 1H NMR (400 MHz / CDCl3) d: 7.2-7.6 (m, 4H, Ts CH), 3.5 (d, 2H, J = 
11.4 Hz, CH2), 2.6 (td, 2H, J = 13.5, 4.7 Hz, CH2), 1.5 (d, 2H, J = 12.5 Hz, CH2), 1.4 (d, 2H, J = 7.2 Hz, 
CH2), and 1.2 (m, 4H).
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But-3-yn-1-yl 4-methylbenzenesulfonate
3-Butyn-1ol (1 ml, 13.2 mmol, 1.0 eq.) was stirred in dichloromethane (12 ml) and the solution 
cooled to 0 °C. p-Toluenesulfonyl chloride (3.8 g, 20 mmol, 1.5 eq.) was added, followed by 
pyridine (2.2 ml, 28.4 mmol, 2.16 eq.). The resulting reaction mixture was stirred at 0°C for 3h and 
then was diluted with ether (35 ml) and the solution washed consecutively with water (2 x 30 ml), 
1M HCl (2 x 30 ml), 2M aqueous NaOH (2 x 30 ml) and brine (30 ml), and then dried over MgSO4, 
filtered and evaporated. The crude product was purified by column chromatography, eluting with 
30% petrol in DCM, to give the pure title compound (1.86 g, 77%). 1H NMR (400 MHz / CDCl3) d: 
7.9 (d, 2H, Ts CH), 7.4 (d, 2H, Ts CH), 4.2 (t, 2H, CH2), 2.6 (dt, 2H, CH2), 2.4 (s, 3H, Ts CH3), and 
2.0 (t, 1H, CH).
But-3-yn-1 methanesulfonate
But-3-yn-1-ol (1.08 ml, 14.2 mmol) was dissolved in dichloromethane (10 ml) and the solution 
cooled to 0°C. Triethylamine (9.94 ml, 71 mmol, 5 eq.) was added, followed by methanesulfonyl 
chloride (1.33ml, 17.0 mmol, 1.2 eq.). The reaction mixture was stirred at 0 °C for 1h and then was 
diluted with water (10 ml) and extracted with dichloromethane (3 × 10 ml). The combined organic 
layers were washed with water (2 x 10 ml) and brine (2 x 10 ml) then dried over MgSO4, filtered and 
evaporated to give the title compound as a colourless oil (1.90 g, 90%). 1H NMR (400 MHz / CDCl3) 
d: 4.3 (t, 2H, J = 6.6 Hz, CH2), 3.0 (s, 3H, Ms CH3), 2.6 (dt, 2H, J = 2.6, 9.3 Hz, CH2), 2.0 (t, 1H, J = 
2.6 Hz, CH).
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Methyl (4-hydroxybutyl)carbamate 169
4Amino-1-butanol (0.5 mL, 0.484 g, 5.42 mmol) was dissolved in dry DCM (5 mL) and cooled 
down to 0oC. Et3N (0.83 mL, 0.604 g, 5.97 mmol) was added dropwise, followed by methyl 
chloroformate (0.461 mL, 0.564 g, 5.97 mmol) in DCM (5 mL). The reaction mixture was allowed 
to slowly warm up to room temperature and stirred for 2h. The solvent was evaporated and the 
residue purified by column chromatography, eluting the carbamate 169 (0.72g, 90%) as a colorless
oil. 1H NMR (400 MHz / CDCl3) d: 4.9 (br. s, 1H, NH), 3.6 (s, 3H, OCH3), 3.2 (q, 2H, J = 7.4 Hz, 
CH2N), 2.1 (br. s, 1H, OH), 1.6 (dt, 2H, J = 7.4, 3.0 Hz, CH2), and 1.4 (t, 2H, J = 7.4 Hz, CH2OH).
Methyl (4-(benzo[d]thiazol-2-ylthio)butyl)carbamate 170
To a stirred solution of the alcohol 169 (0.05g, 0.340 mmol, 1 eq.) in anhydrous THF (5ml) at room 
temperature under N2 was added 2mercapto1,3benzothiazole (0.068 mg, 0.41 mmol, 1.2 eq.) and 
triphenylphosphine (0.107g, 0.407 mmol, 1.2 eq.). The resulting solution was cooled to 0oC and 
diisopropyl azodicarboxylate (0.09g, 0.088 mL, 0.890 0.445 mmol, 1.3 eq.) added dropwise. The 
cooling bath was removed and the mixture stirred for 2h. The solvent was removed in vacuum and 
the residue further purified via column chromatography (eluting with 3% EtOAc in hexanes) to give 
the titled compound 170 as a colourless oil (0.009 g, Yield: 9%). 1H NMR (400 MHz / CDCl3) d: 
7.3-7.8 (m, 4H, Ts CH), 3.7 (s, 3H, OCH3), 3.6 (t, 2H, J = 7.0 Hz, CH2S), 3.2 (t, 2H, J = 6.9 Hz, CH2N), 
1.7 (dt, 2H, J = 3.0, 7.0 Hz, CH2), and 1.58 (t, 2H, J = 7.0 Hz, CH2OH).
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Methyl (4-(benzo[d]thiazol-2-ylsulfonyl)butyl)carbamate 171
To a solution of thioether 170 (0.134 g, 0.452 mmol, 1 eq.) in methanol (10 mL) at 0oC was added 
sodium tungstate dihydrate (0.037 g, 0.113 mmol, 0.25 eq.) followed by 30% aqueous H2O2 (0.153 g, 
4.52 mmol, 10 eq.). The reaction mixture was allowed to warm to room temperature and stirred for 
24h. The reaction was then diluted with DCM (10 mL) and a solution of 10% aqueous NaHSO3 was 
added. The biphasic mixture was stirred for 15 min and the layers were separated. The aqueous layer 
was washed with DCM (2 x 25 mL) and the combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrated to give the title compound 171 as a colourless oil (0.04g, 
yield: 27%). 1H NMR (400 MHz / CDCl3) d: 7.7-8.3 (m, 4H, Ts CH), 3.8 (s, 3H, OCH3), 3.6 (t, 2H, J 
= 7.4 Hz, CH2S), 3.2 (t, 2H, J = 6.9 Hz, CH2N), 1.7 (dt, 2H, J = 6.9, 7.4 Hz, CH2), and 1.6 (t, 2H, J = 
7.4 Hz, CH2OH).
4-((Methoxycarbonyl)amino)butyl methanesulfonate 176
The alcohol (200 mg, 1.36 mmol) was dissolved in dichloromethane (10 ml) and cooled to 0°C. 
Triethylamine (0.436 ml, 6.80 mmol) was added, followed by methanesulfonyl chloride (0.126 ml, 
1.63 mmol). The reaction mixture was stirred at 0°C for 1h. The reaction mixture was extracted with 
water (3 x 30 ml), 2M HCl (2 x 30 ml) and 2M NaOH (2 x 30 ml), then dried over Na2SO4 and 
evaporated to give the titled compound 176 as a colourless oil (0.20 g, yield: 98%). 1H NMR (400 
MHz / CDCl3) d: 4.5 (t, 2H, J = 7.4 Hz, CH2O), 3.8 (s, 3H, OCH3), 3.2 (t, 2H, J = 7.4 Hz, CH2N), 3.0
(s, 3H, Ms CH3), 2.0 (t, 2H, J = 7.4 Hz, CH2) and 1.7 (t, 2H, J = 7.4 Hz, CH2).
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2-(Butylthio)benzo[d]thiazole 181
1-Bromobutane 180 (1 ml, 9.3 mmol) was dissolved in dichloromethane (15 ml) and 
2mercapto-1,3-benzothiazole (1.56 g, 9.3 mmol) was added. Triethylamine (2.6 ml, 18.6 mmol) 
was added slowly. The resulting mixture was stirred at room temperature for 19h. After the reaction 
was completed, the reaction mixture was washed with 2M HCl (2 x 15 ml) and saturated aqueous 
sodium carbonate (20 ml), then dried over Na2SO4, filtered and evaporated to give the title 
compound 181 as a colourless oil (1.60 g, 76%). 1H NMR (400 MHz / CDCl3) d: 7.8 (t, 1H, CH), 7.6
(t, 1H, CH), 7.4 (m, 1H, CH), 7.2 (m, 1H, CH), 3.2 (t, 2H, J=7.3 Hz, CH2Br), 1.7 (m, 2H, CH2), 1.4 
(m, 2H, CH2), and 0.83 (t, 3H, J=7.4 Hz, CH3). LRMS m/z calcd. for C12H15NO3S [M+H]+ = 223; 
found: 223.
5-Cyclohexylidenepentanoic acid 183
A solution of 4-carboxybutyltriphenylphosphonium bromide (5.43 g, 12.2 mmol) in anhydrous THF 
(20 ml) was treated with potassium bis(trimethylsilyl)amide (4.88 g, 24.8 mmol), and the resulting 
orange mixture was stirred at room temperature for 15 min. A solution of cyclohexanone (300 mg, 
3.06 mmol) in anhydrous THF (10 ml) was then added and the resulting heterogeneous mixture 
stirred at room temperature for 3h. The reaction was quenched with water (10 ml), and the water 
layer was extracted with ether to remove the unreacted cyclohexanone. The water layer was then 
acidified with 10% HCl to pH 2, and extracted with ethyl acetate. The combined organic extracts 
were washed with brine and then dried with MgSO4. The solvent was evaporated in vacuo to give 
the title product 183 as a colourless oil (0.38 g, 67%). 1H NMR (400 MHz / CDCl3) d: 4.9 (t, J = 7.4 
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Hz, 1H, CH=C), 2.2 (t, J = 7.2 Hz, 2H, CH2CO), 2.0-1.9 (m, 6H, CH2), and 1.6-1.4 (m, 8H, CH2). 
13C NMR (125 MHz/ CDCl3) d: 180.4(COOH), 140.9 (C=CH), 129.6 (C=CH), 37.2 (CH2), 33.4 
(CH2), 28.7 (CH2), 28.7 (CH2), 27.8 (CH2), 26.9 (CH2), 26.3 (CH2), 25.0 (CH2).
Methyl (4-cyclohexylidenebutyl)carbamate 184
Diphenylphosphoryl azide (0.311 ml, 1.25 mmol) and triethylamine (0.201 ml, 1.45 mmol) were 
added to a solution of the foregoing cyclohexylidenepentanoic acid 183 (0.24 g, 1.32 mmol) in dry 
toluene (7 ml). The reaction mixture was heated under reflux for 1h under N2. Zinc chloride (0.5M 
in THF, 0.262 ml, 0.132 mmol) and methanol (3.2 ml) were added and the mixture was heated under 
reflux for 1h. After the reaction was completed, the reaction mixture was extracted, and then dried 
over MgSO4, filtered and evaporated to give the carbamate 184 as a colourless oil (0.28 g, 18%). 1H 
NMR (400 MHz / CDCl3) d: 4.94 (t, J = 14.6 Hz, 1H, CH=C), 4.80 (br s, 1H, NH), 3.58 (s, 3H, 
CO2CH3), 2.0 -1.9 (m, 6H, 3 x CH2), and 1.4 - 2.0 (m, 10H, 5 x CH2). 13C NMR (125 MHz/ CDCl3) 
d: 157.4 (CO), 140.6 (C=CH), 125.4 (C=CH), 51.9 (OCH3), 40.8 (CH2N), 37.1 (CH2), 30.3 (CH2), 
29.8 (CH2), 28.6 (CH2), 27.8 (CH2), 26.9 (CH2), 26.9 (CH2), 24.3 (CH2). HRMS (EI) m/z calcd. For
C12H21NO2 [M]+ = 2112.1651, found: 212.1660.
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Methyl 2-cyclohexylpyrrolidine-1-carboxylate 188
The carbamate 184 (0.188 g, 0.558 mmol, 1 eq.) was dissolved in dichloromethane (5 ml), to which 
was added triflic acid (0.025ml, 0.247 mmol, 0.5 eq.) and stirred at 0°C for 30 mins. The reaction 
was quenched by the addition of saturated aqueous K2CO3 (15 m) and the two layers were separated. 
The aqueous layer was extracted with dichloromethane (2 x 20 ml), the combined organic layers 
were dried over MgSO4, filtered, and evaporated to give the title compound 188 as a colourless oil 
(0.05 mg, Yield: 42%). 1H NMR (400 MHz/ CDCl3) d: 3.6 (s, 3H, OCH3), 3.4 (t, 2H, J=6.0 Hz, 
NCH2), 3.1 (app. q, CHN), 2.51 (dt, 2H, CHCH), 1.6- 1.3 (m, 14H, 7XCH2). 13C NMR (125 MHz/ 
CDCl3) d: 156.4 (CO), 58.9 (CH) 51.7 (OCH3), 40.7 (CH), 33.4 (CH2), 33.1 (CH2), 31.1 (CH2), 26.7 
(CH2), 26.4 (CH2), 25.6 (CH2), 23.5 (CH2), 22.8 (CH2). HRMS m/z calcd. for C12H21NO2 [M]+ = 
211.1572, found: 211.1573.
Methyl 2,2dimethoxyethyl carbamate 196
To a solution of amino acetaldehyde dimethyl acetal (10 ml, 89 mmol, 1.0 eq.) in dichloromethane 
(100 ml) at 0oC triethylamine (27.3 ml, 196 mmol, 2.2 eq.) was added dropwise, followed by the 
dropwise addition of methyl chloroformate (8.27 ml, 107 mmol, 1.2 eq.). The resulting solution was 
allowed to warm to room temperature and stirred overnight. The solution was diluted by the addition 
of dichloromethane and washed with 0.2M hydrochloric acid (3 x 50 mL), water (4 x 50 mL) and 
brine (2 x 50 mL). The combined organic layers were then dried over MgSO4, filtered and 
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evaporated to give the title compound 196 as an orange oil (9.87 g, 68%); 1H NMR (400 MHz / 
CDCl3) d: 4.9 (br s, 1H, NH), 4.3 (t, 1H, J = 5.4 Hz, CH(OMe)2), 3.6 (s, 3H, CH3O2C), 3.4 (s, 6H, 2 
x OCH3), 3.25 (app dd, 2H, J = 5.4, 2.1 Hz, CH2N)
Methyl N-(1,3dithian2-ylmethyl)carbamate 197
To a solution of the carbamate 196 (4.08 g, 25.0 mmol, 1 eq.) in dichloromethane (50 ml) at 0oC,
1,3-propanedithiol (2.51 mL, 25.0 mmol, 1 eq.) was added dropwise, followed by the addition of 
boron trifluoride diethyl etherate (8.15 mL, 50.3 mmol, 2.1 eq.). The mixture was allowed to stir for 
6h at 0oC before warming to room temperature. The mixture was then poured into aqueous 2M 
potassium hydroxide (100 mL) and the organic layer separated. This organic layer was washed with 
brine (3 x 25 mL), dried with MgSO4, filtered and evaporated to give the title compound 197 as a 
chalky white solid (3.89 g, 90%); m.p. 7577oC. 1H NMR (400 MHz / CDCl3) d: 5.49 (1H, br, s, 
NH), 3.95 (1H, t, J = 7.1 Hz, CHS2), 3.57 (3H, s, CH3O2C), 3.46 (2H, t, J = 6.4, CH2N), 2.81 (2H, 
ddd, J = 14.0, 7.0, 2.4 Hz, 2 x SCH2), 2.66 (2H, td, J = 9.6, 2.4 Hz, 2 x SCH2), 2.011.94 (1H, m, 
SCH2CHA), 1.87-1.79 (1H, m, SCH2CHB). 13C NMR (125 MHz/CDCl3) d: 156.9 (C=O), 52.2 
(CH3O2C), 45.4 (CHS2), 44.3 (CH3N), 28 (2 x CH2), 25.6 (CH2).112
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1-Vinylcyclohexanol 198
To a THF solution (20 mL) of cyclohexanone (1.96 g, 2.07 mL, 20 mmol, 1 equiv.) was added 
vinylmagnesium bromide (30 mL, 30 mmol, 1.5 equiv.). After stirring for 16h at room temperature, 
an aqueous solution of NH4Cl (50 mL, 1M) was added. The organic and aqueous layers were 
separated and the aqueous layer was extracted with ether (3 x 50 mL). The combined organic layers 
were dried over MgSO4, filtered and the filtrate evaporated. The residue was purified by column 
chromatography (silica gel, petroleum ether/ether = 10:1) to give the title compound 198 as a 
colourless oil (1.94g, 77%). 1H NMR (400 MHz / CDCl3) d: 5.8 (dd, 1H, J = 9.5, 16.7 Hz, CH), 5.2 
(dd, 1H, J = 16.7, 1.3 Hz, CH), 4.9 (dd, 1H, J = 9.5, 1.3 Hz, CH), and 1.4-1.5 (m, 10H, 5 x CH2).
b-Cyclohexylideneethyl bromide 199
To 1-vinylcyclohexanol 198 (0.203 g, 1.61 mol) containing anhydrous pyridine (0.013 mL) in 3mL 
anhydrous petroleum ether (b. p. 4060oc) was added phosphorus tribromide (0.189 mL, 2.01mmol) 
dropwise under efficient cooling and stirring. The solution was kept for 16h at room temperature, 
then decomposed with icecold water (5 mL) and extracted with petroleum ether (5 mL). The 
petroleum ether extracts were washed free of acid with saturated salt solution and finally with dilute 
sodium bicarbonate solution, and water, dried over Na2SO4, and the solvent removed under vacuum 
and the residue distilled to give the title compound 199 (0.14 g, yield: 46%). 1H NMR (400 MHz / 
CDCl3) d: 5.4 (td, 1H, J = 7.5, 1.1 Hz, CH) 3.9 (d, 2H, J = 7.5 Hz, CH2), and 1.4 - 1.5 (m, 10H, 5 x 
CH2).
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b-Cyclohexylideneethyl chloride 201 
To a magnetically stirred solution of the alcohol 190 (0.316 g, 2 mmol, 1 equiv.) in DCM (10 ml) 
was added AcCl (0.213 ml, 3 mmol, 1.5 equiv.). The mixture was stirred at room temperature. After 
addition of H2O (25 mL), the organic layer was separated and washed with aqueous NaHCO3
solution (25 mL) and H2O (25 mL) then dried over anhydrous sodium sulfate and concentrated in
vacuo to give the chloride 201 (0.341 g, yield: 94%). 1H NMR (400 MHz / CDCl3) d: 5.3 (t, 1H, J =
8.0 Hz, CH), 4.1 (d, 2H, J = 8.0 Hz, CH2Cl), and 1.6-1.9 (m, 10H, 5 x CH2).
Methyl ((1,3-dithian-2-yl)methyl)(3-cyclohexylidenepropyl)carbamate 202
To a stirred solution of dithiane 196 (0.230 g, 1.11 mmol, 1.5 eq.) in THF (15 ml) at -40 oC was 
added a 2.5M solution of nBuLi in hexanes (0.086 ml, 2.3 mmol, 3.1 eq.). The resulting solution 
was stirred for 2h at 20 oC. The solution was then cooled to 78oC and DMPU (0.57 ml, 4.44 mmol, 
6 eq.) was added dropwise and the solution was stirred for a further 1h at -78oC. The solution was 
carefully transferred by cannula to a solution of bromide 199 (0.14 g, 0.7 mmol, 1.0 eq.) in THF (10 
ml) at -78oC. The reaction mixture was stirred at 78oC for 4h followed by warming slowly to -20oC 
and kept in the freezer overnight. The reaction mixture was then poured into ice water (50 ml) and 
the aqueous layer was extracted with ether (5 x 20 ml). The combined organic layers were dried over 
MgSO4 then filtered and evaporated to give the crude title product. The crude mixture was separated 
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by column chromatography using 15% ethyl acetate in hexane to give the titled compound 202 as a 
pale oil (0.19g, yield: 81%). 1H NMR (400 MHz / CDCl3) d: 5.2 (app. t, 1H, J = 6.9 Hz, CH=C), 4.0 
(t, 1H, J = 4.1 Hz, CHS), 3.6 (s, 3H, OCH3), 3.5 (t, 2H, J = 6.1 Hz, CH2N), 3.5 (t, 2H, J = 4.1 Hz, 
CH2CH2), 2.8 (ddd, 2H, J = 14.0, 7.0, 2.4 2 x SCH2), 2.7 (2H, td, J = 9.6, 2.4 Hz, 2 x SCH2), 2.0 –
1.9 (1H, m, SCH2CHa), 1.9 - 1.8 (1H, m, SCH2CHb) and 1.5 (m, 10H, 5 x CH2). 
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Methyl ((1,3-dithian-2-yl)methyl)(3-methylbut-2-en-1-yl)carbamate 204
To a stirred solution of dithiane 199 (1.43 g, 6.9 mmol, 1.5 eq.) in THF (37.5 ml) at -40oC was 
added a 2.5M solution of n-BuLi in hexanes (5.7 ml, 14.28 mmol, 3.1 eq.). The resulting solution 
was stirred for 2h at -20oC. The solution was then cooled to 78oC and DMPU (3.38 ml, 27.7 mmol) 
was added dropwise and the solution was stirred for a further 1h at 78oC. The solution was carefully 
transferred by cannula to a solution of 1bromo-3-methyl-2-butene (0.536 ml, 4.61 mmol, 1 eq.) in 
THF (20 ml) at 78oC. The reaction mixture was stirred at -78 oC for 4h followed by warming slowly 
to -20oC and kept in the freezer overnight. The reaction mixture was then poured into ice water (50 
ml) and the aqueous layer was extracted with ether (5 x 20 ml). The combined organic layers were
dried over Mg2SO4 then filtered and evaporated to give the crude title product. The crude mixture 
was separated by column chromatography using 15% ethyl acetate in hexane to give pure 
N-alkylated dithiane 204 as a light yellow oil (0.835g, 44%), as a pair of rotomers.
204a 1H NMR (400 MHz/ CDCl3) d: 5.1 (br. s, 0.43H, C=CH), 4.1 (t, 0.43H, J = 7.4 Hz, SCH), 3.9
(d, 0.43H, J = 5.6 Hz, NCH2CH), 3.6 (s, 0.43H, CO2CH3), 3.4 (d, 0.43H, J = 7.4 Hz, C=CHCH2), 
2.9-2.8 (m, 0.86H, 2 x SCH2), 2.11.9 (m, 0.43H), 1.91.8 (m, 0.43H), and 1.6 (s, 1.29H, 2 x CH3).
13C NMR (125 MHz/ CDCl3) d: 156.9 (CO), 136 (Cq), 120.1 (CH), 52.7 (OCH3), 50.0 (CH2N), 45.7
(SCH2), 44.4 (SCH2CH22), 28.8 (CHCH2N), 25.8 (CH2), and 25.3 (CH3).
204b 1H NMR (400 MHz/ CDCl3) d: 5.1 (br. s, 0.57H, C=CH), 4.1 (t, 0.57H, J = 7.4 Hz, SCH), 3.9
(d, 0.57H, J = 5.6 Hz, NCH2CH), 3.6 (s, 0.57H, CO2CH3), 3.4 (d, 0.57H, J = 7.4 Hz, C=CHCH2), 
2.9 - 2.8 (m, 1.14H, 2 x SCH2), 2.11.9 (m, 0.57H), 1.91.8 (m, 0.57H), and 1.6 (s, 0.57H, CH3). 13C 
NMR (125 MHz/ CDCl3) d: 156.6 (CO), 135.6 (Cq), 120 (CH), 52.7 (OCH3), 49.3 (CH2N), 45.3 
(SCH2), 44.4 (SCH2CH22), 28.2 (CHCH2N), 25.8 (CH2), and 17.9 (CH3). IR (neat) n/cm-1: 2920, 
1702, 1470, 1436, 1228, 1128, 942, 768. LRMS m/z calcd. for C12H21NO2S2 [M]+ = 275, found: 275.
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4-(((1,3-Dithian-2-yl)methyl)(methoxycarbonyl)amino)-2-methylbutan-2-yl 
trifluoromethanesulfonate 206
The dithiane 204 (135 mg, 0.49 mmol, 1 eq.) was dissolved in DCM (5 ml), to which was added 
triflic acid (0.021ml, 0.24mmol, 0.5 eq.) and the solution stirred at 0oC for 30 mins. The reaction 
was quenched by the addition of saturated aqueous K2CO3 (15 m) and the two phases were separated. 
The aqueous layer was extracted with dichloromethane (2 x 20 ml), the combined organic layers 
were dried over Mg2SO4, filtered, and evaporated to give the title compound 206 as a colourless oil 
(103 mg, 49%). 1H NMR (400 MHz/ CDCl3) d: 4.2 (t, 1H, J = 8.0 Hz, SCH), 4.1 (s, 3H, OCH3), 3.9
(d, 2H, J = 8.0 Hz, CH2), 3.7 (t, 2H, J = 6.1 Hz, NCH2), 2.9 - 2.8 (m, 2H, 2 x SCH2), 2.2 (t, 2H, J = 
6.1, CH2C), 2.0 - 1.9 (m, 2H, CH2), 1.5 (s, 6H, 2 x CH3). 13C NMR (125 MHz/ CDCl3) d: 157.0 
(CO), 120.0 (CF3), 91.3 (Cq), 49.9 (CH2N), 49.3 (CH2), 52.6 (OCH3), 28.2 (SCH2), 28.7 (SCH2), 
25.7 (CH2), and 17.8 (CH3).
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